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ABSTRACT 
 
Twist1 is a basic helix-loop-helix transcription factor family that serves as one of the 
master regulators promoting epithelial-mesenchymal transition (EMT). Twist1 has been 
shown in many studies to promote EMT, stemness, invasiveness and metastasis in 
multiple cancers, including breast cancer. However, the genetic role of Twist1 in 
spontaneous breast cancer has not been investigated, and it is also unknown whether 
Twist1 is required for cell invasion and metastasis of spontaneously developed cancer. In 
this study, using a new TVA/RCIP mouse model, we disrupted Twist1 in certain 
mammary luminal epithelial cells and specifically induced tumors from these cells. We 
found that tumor cell-specific knockout of Twist1 diminished lung metastasis without 
affecting primary tumor initiation or growth. The diminished lung metastasis is 
accompanied with the decreased EMT, angiogenesis and circulating tumor cells caused 
by Twist1 knockout.  Twist1 expression was positively associated with late-stage tumors 
and negatively associated with ERα and Foxa1 expression in mouse tumors. We then 
identified Foxa1 as a novel direct target of Twist1 in human breast cancer. We further 
found that Twist1 inhibits Foxa1 expression through direct binding to its proximal 
promoter region and recruiting Mi2/nucleosome remodeling and deacetylase 
(Mi2/NuRD) transcriptional repressor complex in human breast cancer cells. Moreover, 
Twist1 also diminished transcriptional activator AP1 binding to Foxa1 promoter. Twist1 
mediated Foxa1 down-regulation is essential for promoting breast cancer migration, 
invasion and metastasis. Restored Foxa1 expression significantly inhibits Twist1 
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dependent cell migration and invasion capability of MCF7 cells through inhibiting 
integrin α5, β1 and MMP9 expression. Importantly, Twist1high Foxa1low correlates with 
the poorest prognosis in breast cancer patients. These findings highlight Twist1 as a key 
player in promoting breast cancer progression to a more malignant phenotype and a 
potential therapeutic target. 
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1. INTRODUCTION  
 
1.1 Breast cancer  
 
1.1.1 Basic characteristics of cancer 
 
The origin of the word “CANCER” is credited to the Greek physician Hippocrates, who 
is considered the “Father of Western Medicine.” Hippocrates used the 
terms carcinos and carcinoma to describe non-ulcer forming and ulcer-forming tumors. 
Cancer begins when cells in a part of the body start to grow out of control. There are 
many kinds of cancer, but they all start because of out-of-control growth of abnormal 
cells which acquire genetic or epigenetic alterations. In the 2 review papers by D. 
Hanahan and R. Weinberg1, 2, they proposed that these alterations occur in most if not all 
cancer cells which contribute to the 10 hall marks of cancer including: deregulating 
cellular energetics, evading apoptosis, self-sufficiency in growth signals, insensitivity to 
anti-growth signals, avoiding immune destruction, limitless replicative potential, tumor-
promoting inflammation, tissue invasion and metastasis, sustained angiogenesis, genome 
instability and mutation. For most of the solid tumors, the tumor related mortality is due 
to the metastasis to distant organs, which results from the acquired capability of tumor 
cells to invade and metastasize. Tumor metastasis is a multi-step process defined as the 
ability of tumor cells to migrate from its original site to colonize in distant organs3. Each 
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of these steps can be rate limiting, as blocking any of these steps could stop the entire 
process (Fig 1.1). 
 
 
 
Figure 1.1. Overview of cancer metastasis steps. (From Isaiah J. Fidler, Nature 
Review: Cancer, 20033) 
 
 
 
1.1.2 Breast cancer and classification  
 
Breast cancer is a heterogeneous disease with different clinical and pathological features. 
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Classification of breast cancer may help to predict prognosis and direct personalized 
treatment. Comprehensive molecular profiling of breast cancer using microarray-based 
technology4-6 demonstrated that the morphological heterogeneity of breast cancer was 
reflected at the transcriptional level7, 8. Their data show systematic variations of the 
expression profiles of breast cancer. These profiles could classify breast cancers into five 
subtypes: luminal A, luminal B, normal breast-like, ERBB2+ and basal-like breast 
carcinomas4, 6, 8, 9. The basal-like subtype was characterized by high expression of 
keratins 5 and 17, laminin, and FABP7, whereas the ERBB2+ subtype was characterized 
by high expression of several genes in the ERBB2 amplicon at 17q22.24 including 
ERBB2 and GRB7. Normal breast-like group showed the highest expression of many 
genes known expressed in adipose tissue and other non-epithelial cell types. On the other 
hand, luminal type of tumors can be further grouped into two subgroups: luminal 
subtype A, with the highest expression of the ERα gene, GATA3, XBP1, TFF3, Foxa1, 
and LIV-1;  and luminal subtype B with low to moderate expression of the luminal-
specific genes including the ERα cluster4.  
 
More importantly, the molecular profile of tumor will not stay fixed as the progression 
of cancer. Several studies have shown that mouse mammary gland tumors progress from 
ERα positive/luminal A subtype to luminal B or ERα negative subtypes10, 11. Similarly, 
loss of ERα expression is also broadly observed in human breast cancers, concomitant 
with hormone resistance, invasiveness and poor prognosis12. 
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Different gene expression profiles reflect variation in the cellular biology of the tumor 
subtypes and are associated with patients’ clinical outcome8, 9. Luminal A tumors have 
the most favorable prognosis, normal like tumors have an intermediate prognosis4, 5, 9, 13. 
On the other hand, luminal B, ERBB2-positive and basal-like tumors are associated with 
poor relapse-free and overall survival. Basal-like breast cancer (BLBC) is a major 
clinical challenge due to its aggressive nature and the lack of expression of the available 
drug targets including steroid hormone receptors (ER and PR) and ERBB2. BLBCs do 
not response to currently available targeted therapies such as tamoxifen (ER inhibitor) or 
trastuzumab (HER2 inhibitor) therapy. The absence of effective targeted therapies and 
poor response to standard chemotherapy may be associated with poor prognosis of 
BLBC patients. BLBC also has stem-cell-like properties and activated EMT (epithelial-
mesenchymal transition) program, suggesting that EMT regulators may play critical 
roles in BLBC progression. 
 
1.2 EMT 
 
1.2.1 Basics of EMT 
 
Epithelial and mesenchymal cells differ in various functional and phenotypic 
characteristics. Epithelial cells form a single layer or multilayers that are closely 
adjoined through specialized intercellular junctions such as tight junctions, adheren 
junctions, desmosomes and gap junctions14. Epithelial cells also have apical–basolateral 
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polarization, as the epithelial cells are all polarized in the same manner. Every epithelial 
cell membrane can be divided into an apical domain and a basolateral domain, with the 
apical surface facing either the exterior environment or the luminal space and the 
basolateral domain can be further divided to basal subdomain mediating cell-
extracellular matrix adhesion and lateral subdomain involved in cell-cell contact. Cells 
or cell aggregates lacking the above criteria are defined as mesenchymal cells. 
Mesenchymal cells contact neighboring mesenchymal cells only focally and do not 
associate with a basal lamina. In 2D cell culture, mesenchymal cells are characterized by 
spindle shaped, fibroblast-like morphology, whereas epithelial cells grow as clusters that 
maintain cell–cell adhesion. Cultured mesenchymal cells tend to be highly motile. 
Epithelial cells are also motile and can move away from their nearest neighbors, while 
remaining within the epithelial layer. However, cells do not detach and move away from 
the epithelial layer under normal conditions15.  
 
While epithelial and mesenchymal cell types have long been recognized in early 
embryos, the conversion of epithelial cells into mesenchymal cell, which is known as 
epithelial-mesenchymal transition (EMT), was not defined until 1980s. Greenburg and 
Hay showed that when epithelial cells were cultured in 3D collagen gels, these cells 
elongated, detached from the explants, and migrated as individual cells, which are all 
belong to mesenchymal phenotypes16-18. The transition from epithelial- to mesenchymal-
cell characteristics involves a spectrum of inter- and intracellular changes. Subsequent 
molecular studies loosely defined EMT by three major changes in cellular phenotype19, 
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20. The first is morphological changes from monolayer of epithelial cells with an apical-
basal polarity to dispersed, spindle-shaped phenotype. The second is differentiation 
marker changes from cell-cell junction proteins and cytokeratin intermediate filaments to 
vimentin filaments and fibronectin. The third is the functional changes associated with 
the conversion of relative stationary cells to motile cells that can invade through ECM. 
As not all three changes are always observed during EMT, acquisition of the ability to 
migrate and invade ECM as a single cell is then considered a functional hallmark of the 
EMT program. 
 
Several in vitro and in vivo studies aimed to define the molecular regulation of EMT 
showed that EMT can be triggered by a crosstalk of extracellular signals including 
extracellular matrix (ECM) as well as soluble growth factors such as members of the 
TGFβ and fibroblast growth factor (FGF) families, epidermal growth factor (EGF) and 
SF/HGF (Fig 1.2). These growth factors serve as ligands for their cell surface receptors, 
which are activated in response to these ligands and trigger the activation of intracellular 
effector molecules, such as members of the small GTPase family — Ras, Rho and Rac 
and members of the Src tyrosine-kinase family. These effectors are responsible for the 
disassembly of junctional complexes and the changes in cytoskeletal organization during 
EMT. On the other hand, several transcriptional regulators such as zinc-finger 
transcription factors snail21, slug22, ZEB123 and  ZEB2(SIP1)24 and bHLH transcription 
factors E4725 and Twist126 were reported to regulate the changes in gene-expression 
patterns that underlie EMT. 
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Figure 1.2. Overview of the molecular networks that regulate EMT. Signaling 
pathways that are activated by EMT regulators and a limited representation of their 
crosstalk are shown. RTKs (receptor tyrosine kinases); TGFβ ( transforming growth 
factor-β); MMPs (Matrix metalloproteinases); ETaR (endothelin-A receptor); FAK 
(focal adhesion kinase); GSK3β ( glycogen-synthase kinase-3 β); H/E(Spl) 
(hairy/enhancer of split) ; ILK (integrin-linked kinase); MAPK (mitogen-activated 
protein kinase); NF-B (nuclear factor-B); PAR6 (partitioning-defective protein-6); 
PI3K (phosphatidylinositol3-kinase); PKB (protein kinase-B); ROS (reactive oxygen 
species); TAK1 (TGFβ-activated kinase-1); TGFβR (TGFβ receptor); WntR (Wnt 
receptor). (From Jean Paul Thiery and Jonathan P. Sleeman, Nature Reviews: Molecular 
Cell Biology, 200615) 
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1.2.2 EMT in development 
 
During embryonic development, epithelial sheets can remodel through distinct processes 
and can also convert reversibly or irreversibly into mesenchymal cells through EMT. 
The process has been observed during a variety of tissue remodeling events, including 
mesoderm formation, neural crest development, heart valve development and secondary 
palate formation. Mesoderm formation and neural crest development occur during early 
embryonic development, epithelial cells undergo EMT, resulting in mesenchymal and 
neural crest cells that maintain the potential to further differentiate into various cell 
types. On the other hand, during heart valve development and secondary palate 
formation, EMT occurs in relatively well-differentiated epithelial cells that are destined 
to become defined mesenchymal cell types.  
 
The earliest example of an EMT program participating in embryogenesis that been 
reported is the formation of mesoderm from the primitive ectoderm, mainly from model 
organisms including Drosophila and amphibian and avian embryos27. Later studies 
indicate that the same basic principles also happen in mammalian embryos28 as epithelial 
cells lose their tight cell-cell adhesions and remain attached to neighboring cells only by 
sparsely distributed focal contacts. Subsequently, these cells undergo mesenchymal 
differentiation and migrate along the narrow extracellular space underneath the 
ectoderm, indicating the EMT program during gastrulation. Another example of EMT in 
embryogenesis is the generation of the neural crest, a defining tissue of vertebrates, 
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which is composed of a population of precursor cells with the ability to migrate over 
long distances in the embryo. The emergence of neural crest cells begins with the 
presence of a distinct population of cells with rounded and pleiomorphic shapes at the 
boundary between the neural plate and the epidermal ectoderm, the presumptive neural 
crest cells, which proceed to lose N-cadherin-mediated cell-cell adhesion while 
becoming excluded from the neural epithelium29. Detailed studies in avian and mouse 
embryos using immune-labeling and electron microscopic revealed that disruption of the 
basal lamina occurs immediately before or at the onset of neural crest cell migration in 
the cranial regions30, 31. These observations demonstrate that neural crest cells actively 
invade through the basal lamina,  which is , however, not present at the neural fold in the 
trunk region before the onset of neural crest migration32. These findings suggest that 
distinct types of subcellular machineries were employed to initiate EMT, invade the 
ECM, and migrate.  
 
Heart valve in vertebrate embryos, which is derived from a precursor structure known as 
endocardial cushion, begins to form soon after the primitive linear heart tube begins to 
loop. Initially, the myocardial cells secrete a large amount of ECM and create 
endocardial cushions, and then the mesenchymal cells fill the cushion space33. These 
mesenchymal cells were then found to derive from the endocardial cell layer by 
undergoing an EMT34. Upon EMT-inducing stimuli, AV endocardial cells decrease N-
CAM, lose cell-cell adhesion, and invade the newly deposited endocardial cushion, 
thereby establishing the presumptive cardiac septa and valves35. Another well-studied 
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EMT is the formation of the secondary oral palate when researchers can trace the entire 
program of palate remolding with electron microscopy and immunohistochemistry by 
dissecting the palatal tissue and introducing it into organ cultures. As fusion of the 
palatal shelves at the midline is required for development of the secondary palate, when 
the shelves approach one another from opposite sides of the developing oral cavity, 
epithelial cells covering the tip of each shelf intercalate and form the medial epithelial 
seam. Then these medial epithelial cells undergo EMT and are integrated into the 
mesenchymal compartment of the palate to finish the program of palatogenesis36.  
 
1.2.3 EMT in diseases 
 
Under physiological condition, such as embryogenesis, EMT program plays an 
important role. However, as well as many other programs, similar cell changes could be 
recapitulated during pathological processes, such as fibrosis and cancer. Many studies 
have shown a remarkable similarity between the regulatory signaling pathways of EMT 
in physiological and pathological conditions.  
 
Fibrosis is characterized by increased numbers of myofibroblasts that deposit interstitial 
ECM, and the origin for majority of these fibroblasts is thought to be tubular epithelial 
cells that undergo through EMT37. In animal models of kidney disease, EMT occurs in 
tubular epithelial cells38. Moreover, similar observations have been made in studies of 
human renal fibrosis39. One of the mechanisms could be inflammatory processes in 
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response to injury of tissue lead to increased levels of factors such as TGFβ, EGF and 
FGF2, which have been demonstrated to be EMT stimulators of tubular epithelial cells40. 
Indeed, one study showed that in the peritoneal cavity, renal dialysis causes injury to the 
mesothelial lining and results in EMT of mesothelial cells and finally fibrosis through 
inducing TGFβ expression41, which then has been confirmed in animal models42.  
 
Beside fibrosis, numerous observations showed that EMT plays an important role in the 
progression of multiple cancers, especially in tumor metastasis. Majority of solid tumors 
are carcinomas that originate from epithelial cells. When the carcinoma cells 
metastasize, they must lose cell-cell adhesion and acquire motility, which shares many 
similarities with the extensive cell migration and tissue rearrangements that occur during 
the various developmental events mentioned above. Indeed, this highly conserved EMT 
program has been implicated in giving rise to the dissemination of single carcinoma cells 
from primary epithelial tumors43. Many reports that study the function of EMT 
regulators and transcriptional factors in cancer revealed the central role of these factors 
in facilitating tumor cell migration, invasion and metastasis. 
 
Thus, based on the functional consequences and biological context, EMT is classified 
into 3 distinct types, which are developmental (Type I), fibrosis and wound healing 
(Type II), and cancer (Type III)44. As mentioned above, these 3 types of EMT occur at 
different micro-environmental context and show different characteristics. On the other 
hand, these 3 types of EMT share some common mechanisms. Biomarkers specific to 
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each subtype of EMT and also common to all subtypes have been defined, as 
summarized in a recent review paper of EMT45 (Table 1.1). 
 
Tumor cells metastasize to distant organs is the major reason of mortality in breast 
cancer patients. However, the mechanism by which epithelial tumor cells escape from 
the primary tumor and colonize a distant site is not entirely understood. Numerous 
studies in breast cancer and other cancers have postulated EMT as an important 
mechanism for tumor metastasis. Except for several rare subtypes such as diffuse lobular 
carcinoma, in most breast cancer, similar to other epithelial carcinomas, EMT rarely 
occurs homogenously across the whole tumor. However, the direct evidence of EMT 
existence is not easy to find as once the epithelial tumor cells undergo EMT, they may 
be phenotypically indistinguishable from fibroblasts. In addition, since most metastatic 
lesions exhibit an epithelial phenotype, whether EMT indeed occurs in breast tumor 
progression is still debatable until a transgenic mice study provides direct evidence of 
EMT in the local invasion of tumor cells in breast cancer46. Furthermore, microarray 
analysis of breast tumors showed that certain types of breast cancer cells are primed to 
undergo EMT and spread, such as the basal or triple negative breast cancer subtype 
which exhibits an aggressive phenotype and correlates with the poorest clinical 
outcomes47. Similar results were observed in breast cancer cells lines as basal B subtype 
breast cancer cell lines also display a mesenchymal phenotype48. These work revealed 
the existence of EMT in primary breast cancer, which is supported by more and more 
evidence to be a reversible and transient process. This could explain why metastatic cells 
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at a secondary site are likely undergo a reversion EMT or MET, permitting colonization 
of the distant site49.  
 
1.2.4 EMT in breast cancer 
 
It was hypothesized that developmental programs are reactivated during tumorigenesis 
and contribute to tumor progression. The fact that numerous EMT regulators in 
development are also inappropriately expressed in human cancer and correlate with 
features of EMT is a strong evidence to support the hypothesis22, 23, 26. E-cadherin, an 
important caretaker of the epithelial phenotype, is down-regulated by these EMT 
transcriptional regulators. In both cell culture and tumor mouse models, ectopically 
expression of E-cadherin in certain invasive carcinoma cells can inhibit their capability 
to invade and metastasize. Conversely, downregulation of E-cadherin (or mutations that 
occur in cancer) has several important consequences that are of direct relevance to EMT 
and subsequent cell motility and metastasis. Decrease of E-cadherin level in carcinoma 
cells results in the loss of E-cadherin-dependent intercellular epithelial junctional 
complexes, and abolished sequestering of β-catenin in the cytoplasm, subsequently 
release the carcinoma cells from the neighbor cells. 
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Acquired markers Attenuated markers 
Name EMT type Name EMT type 
Cell-surface 
proteins 
N-cadherin 1,2 E-cadherin 1,2,3 
OB-cadherin 3 ZO-1 1,2,3 
α5β1 integrin 1,3 
αVβ6 integrin 1,3 
Syndecan-1 1,3 
Cytoskeleton 
markers 
FSP1 1,2,3 Cytokeratin 1,2,3 
α-SMA 2,3 
Vimentin 1,2 
β-catenin 1,2,3 
ECM proteins 
α1(I) collagen 1,3 α1(IV) collagen 1,2,3 
α1(III) collagen  1,3 Laminin 1 1,2,3 
Fibronectin  1,2 
Laminin 5  1,2 
Transcription 
factors 
Snail1 1,2,3   
Snail2 1,2,3   
ZEB1 1,2,3   
CBF-A/KAP-1 
complex 2,3   
Twist1 1,2,3   
LEF-1 1,2,3   
Ets-1 1,2,3   
FOXC2 1,2   
Goosecoid 1,2   
MicroRNAs    
miR10b 2 Mir-200 family 2 
miR-21 2,3   
Table 1.1. Markers of EMT (From Michael Zeisberg and Eric G. Neilson, J.Clin. 
Invest, 200945) 
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Besides promoting tumor cell invasion and metastasis, EMT is reported to be involved in 
multiple aspects of tumor progression including cell survival, chemo-resistance, 
stemness and cancer cell transition into endothelial cells50 (Fig 1.3). For example, Robert 
A. Weinberg’s group reported that the induction of EMT in immortalized human 
mammary epithelial cells (HMLEs) results in the acquisition of mesenchymal traits and 
in the expression of stem cell markers. Moreover, stem-like cells isolated from HMLEs, 
mouse or human mammary glands and mammary carcinomas undergo EMT51. They 
then update their study recently showing that distinct EMT programs control normal 
mammary stem cells and tumor-initiating cells52. Another study showed that Six1 
expands the mouse mammary epithelial stem/progenitor cell pool, which is correlated 
with EMT53. The acquisition of a cancer stem cell-like phenotype enables a subset of 
tumor cells to self-renew and likely to ultimately metastasize to distant organs.  
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Figure 1.3 Consequences of EMT in breast cancer cells. In addition to the well-
characterized role for EMT in local spread of tumor cells, induction of EMT also 
correlates with numerous other properties including a tumor-initiating cell phenotype, 
resistance to chemotherapy and senescence, evasion of the immune system and induction 
of a basal gene expression profile. (From Douglas S. Micalizzi, Susan M. Farabaugh, 
Heide L. Ford, J Mammary Gland Biol Neoplasia, 201050)	
	
	
	
1.3 Twist1  
 
1.3.1 Twist1 in development and human disease 
 
A mutant Drosophila embryos failed to gastrulate normally, produced no mesoderm and 
died at the end of embryogenesis with a ‘twisted’ appearance54 , thus the gene that is 
responsible for the phenotype is named “twist”. The human and mouse homolog of twist 
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gene are found and named Twist1. The twist gene encodes a transcription factor 
containing a basic helix-loop-helix (bHLH) domain55 involved in the regulation of 
organogenesis56, 57.The critical roles of Twist1 protein in mesoderm associated 
organogenesis, especially in the morphogenesis of the cranial neural tube58, have been 
well illustrated by genetic studies.  In Drosophila, twist transcription is activated by 
Dorsal in the presumptive mesoderm and the expressed twist protein forms a steep 
gradient across the presumptive mesoderm-neuroectoderm border in the early embryo59, 
60. During later stage, twist expression decreases to relatively low levels in the 
mesodermal layer cells. The similar effect of Twist1 is found in mouse mesoderm 
development. After birth, Twist1 can be seen in adult mesenchymal cells such as muscle 
stem cells, referred to as adult muscle precursors in Drosophila, while in mouse, Twist1 
is expressed in the adult stem cells of the mesenchyme61, 62. Previous study in our lab 
revealed that Twist1 is expressed in a few tissues, including fibroblasts of the mammary 
glands and dermal papilla cells of the hair follicles in young and adult mice. Conditional 
Twist1 knockout in 6-week-old males and female mice did not influence body weight 
gain, heart rate, or total lean and fat components. The knockout also did not alter blood 
pressure in males, although it slightly reduced blood pressure in females. These results 
indicate that Twist1 is not essential for maintaining an overall healthy condition in 
young and adult mice63.  In summary, Twist1 is highly expressed in the mesoderm-
derived mesenchyme during embryonic development and is primarily expressed in 
relatively quiescent adult stem cells located in mesoderm-derived mesenchymal tissues 
postnatally64. 
  18
In humans, Twist1 gene mutations are responsible for an autosomal dominant inheritance 
disease named Saethre-Chotzen syndrome (SCS), which is characterized by a broad 
spectrum of malformations including short stature, craniosynostoses, high forehead, 
ptosis, small ears with prominent crus, and maxillary hypoplasia with a narrow and high 
palate65, 66. Non-sense mutations and mis-sense mutations at conserved residue across 
species within bHLH domain were found in human SCS patients. Since majority of 
mutations are heterozygous, leading to loss of function of Twist1 protein, it suggests that 
protein level is essential for the function of Twist1 in cells, which is supported by the 
gradient expression of Twist1 protein at the development stage in Drosophila. Gene 
ablation experiments of mouse models demonstrated that the heterozygous Twist1 null 
mice58 manifest craniofacial and limb abnormalities resembling those in SCS patients. 
Since the last decade, numerous studies have shown that Twist1 also plays important 
roles in cancer progression, especially in cancer metastasis26, 67, 68. 
 
1.3.2 Twist1 promotes EMT in cancer 
 
Yang et al.26 reported that increased Twist1 expression correlates with breast cancer cell 
invasion and metastasis, and suppression of Twist1 expression inhibits the cells’ 
capability to metastasize from the xenograft tumor cells in mammary gland to the lung. 
They also observed that expression of Twist1 protein in the epithelial cell lines results in 
partial EMT and induction of cell motility. Subsequent studies revealed that Twist1 
promotes cancer cell survival, drug resistance, cancer stem-like cell number, 
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invadopodia formation for extracellular matrix degradation, and cancer cell transition 
into endothelial cells, respectively12, 69-72. Previous studies revealed several regulators of 
Twist1 and Twist1 target genes in breast cancer. Ling and Arlinghaus73 observed that 
knockdown of STAT3 eliminated Twist1 expression, which does not affect cells 
proliferation but impair cell invasiveness. These observations suggest that STAT3 
enhances Twist1 expression in its promotion of breast cancer progression. Another 
study74 showed that activation of STAT3 increased Twist1 expression while inhibition of 
STAT3 significantly reduced Twist1 expression in the aggressive human breast cancer 
cell lines. This study also showed that STAT3 binds directly to the second proximal 
STAT3-binding site on the human Twist1 promoter and activates Twist1 transcription. 
Together with another observation that Twist1 transcriptionally induces AKT2 to 
promote oncogenic functions75. Cheng et al.70 proposed that STAT3, Twist1 and AKT2 
form a functional signaling axis to enhance tumor invasion, which suggests an attractive 
target for cancer therapy. Interestingly, a recent study demonstrates that AKT1 inhibits 
EMT in breast cancer through Twist1 degradation76. Our group found that the steroid 
receptor coactivator-1 (SRC-1) specifically promotes breast cancer metastasis without 
affecting primary tumor growth77 in a PyMT mouse breast cancer model. Subsequent 
investigation revealed that SRC-1 serves as a coactivator for the transcription factor 
PEA3 to enhance Twist1 expression, suggesting a molecular mechanism by which SRC-
1 promotes breast cancer invasiveness and metastasis78. A recent study showed an 
inverse relationship between TRIM29 and Twist1 and more importantly, TRIM29 and 
Twist1 inhibit each other in breast cancer cells79. Twist1 also plays a critical role in 
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transducing the mechanical signal through G3BP2, which explains how matrix stiffness 
drives EMT and tumor metastasis80. 
 
 
Figure 1.4. Possible regulatory network of Twist1 in cancer progression.Twist1 is 
activated at transcriptional and post-transcriptional levels and promotes EMT, invasion, 
migration, metastasis, cancer stemness and chemo-resistance through multiple signaling 
pathways. (From Qian Qin, Young Xu, Tao He, Chunlin Qin, Jianming Xu, Cell 
Research, 201164)	
	
	
	
As a transcription factor, Twist1 could either activate or repress its target genes. SET8 is 
a member of methyltransferase family that specifically targets H4K20 for 
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monomethylation81, 82 and is implicated in regulating either activation83 or repression82 
of gene transcription. Feng Yang84 and colleagues reported that SET8 physically 
associates with Twist1 to act as a dual epigenetic modifier of Twist1 target genes: 
repressing E-cadherin and activating N-cadherin. A recent study by Jian Shi85 and 
colleagues demonstrated that Twist1 binds to BRD4 thereby constructing an activated 
Twist1/BRD4/P-TEFb/RNA-Pol II complex at the WNT5A promoter and enhancer to 
promote invasion, cancer stem cell (CSC)-like properties, and tumorigenicity of BLBC 
cells. Fu et al. reported that Twist1 interacts with several components of the 
Mi2/nucleosome remodeling and deacetylase (Mi2/NuRD) protein complex, including 
metastasis-associated protein 2 (MTA2), Rb-associated protein 46 (RbAp46), Mi2 and 
histone deacetylase 2 (HDAC2)68. Twist1 recruits this gene repression protein complex 
to the E-cadherin promoter, resulting in repression of the E-cadherin promoter activity 
and E-cadherin expression. Another study showed that Twist1 recruited DNA 
methyltransferase 3B (DNMT3B) to the ERα promoter, leading to a significantly higher 
degree of ERα promoter methylation. Furthermore, they demonstrated that Twist1 
interacted with histone deacetylase 1 (HDAC1) at the ERα promoter, causing histone 
deacetylation and chromatin condensation, further reducing ERα transcript levels12. 
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Figure 1.5. Twist1 recruits Mi-2/NuRD complex to repress E-cadherin 
transcription in cancer progression. Twist1 forms heterodimer with E12, and 
physically interact with MTA2 (metastasis-associated protein 2), RbAp46 (Rb-
associated protein 46) and Mi-2 in the Mi-2/NuRD transcription repressor complex.  
(From Qian Qin, Young Xu, Tao He, Chunlin Qin, Jianming Xu, Cell Research, 201164) 
 
 
 
1.4 Foxa1  
 
1.4.1 Foxa1 in development  
Hepatocyte Nuclear Factor (HNF) was initially cloned and purified from mammalian 
liver, and then found also expressed in other organs.  Later on, the HNF superfamily was 
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identified as sharing a highly conserved central motif with that of the Drosophila 
melanogaster forkhead protein (fkh), known to bind DNA and regulate processes 
necessary for early fly development. The HNF transcriptional regulators represent a 
unique subclass of DNA binding proteins that play a critical role in tissue-specific 
differentiation and organogenesis86-88. The subsequent genome-wide analysis in multiple 
systems uncovered hundreds of forkhead transcription factors, over 40 of which were 
known to be expressed in mammalian systems that could be classified into more than 19 
subclasses89. To better clarify the nomenclature, the vertebrate HNF family was renamed 
“FOX” for Forkhead Box, with a letter showing the subclass, such as FOXA, FOXB90. 
The FOXA family which contains 3 members (Foxa1, FOXA2 and FOXA3) plays 
pivotal roles in mammalian embryonic development and organogenesis. 
 
Foxa1 is expressed in the liver, pancreas, bladder, prostate, colon, lung as well as 
mammary gland in mice. Early studies showed that Foxa1 and another family member 
Foxa2 display overlapping roles in development and differentiation of the pancreas, liver 
and neurological system. On the other hand, Foxa1 alone appears to be the master 
regulator in tissues that dependent on sex hormone signaling, such as the breast and 
prostate glands. In the developing mammary gland, Foxa1 and ERα are co-expressed 
within luminal epithelial cells, with strong expression observed in the terminal end buds. 
Foxa1 deletion results in phenotype similar to ERα null phenotype in ductal 
morphogenesis but not in alveologenesis. Foxa1 may also play a role in sustaining the 
luminal epithelium in an undifferentiated state.91  
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1.4.2 Foxa1 in human cancers 
Foxa1 and FOXA2 were reported to play various roles in multiple human cancers, 
including pancreatic cancer, thyroid cancer, prostate cancer and breast cancer92. The 
relationship between Foxa1 and nuclear receptors has gained a lot of attention ever since 
the identification of this co-factor. Mapping of ERα specific binding sites on 
chromosomes 21 and 22 showed that ERα predominantly occupies enhancer-like regions 
near oestrogen responsive genes. And remarkably, they found forkhead motifs enriched 
in 56% of ERα-bound chromatin at nearby region. Further analyses revealed that Foxa1 
occupies these regions even before ERα was recruited and serves as a pioneer 
transcription factor that facilitates an open chromatin structure in the absence of 
estrogen.93-96  
 
Several studies have shown that Foxa1 is required for optimum expression of around 
50% of ERα regulated genes and estrogen-induced proliferation. 93, 94, 97 Sunil Badve et 
al did immunohistochemistry for Foxa1 protein in breast carcinoma tissues of 438 
patients and correlated Foxa1 expression with various established disease markers and 
with breast cancer-specific survival. They conclude that Foxa1 expression is associated 
with ERα positivity, the luminal subtype A, and better breast cancer specific survival.98 
Concomitant studies showed similar result and also indicated Foxa1 is a critical 
determinant of ERα activity and endocrine response in breast cancer.99, 100 
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Foxa1 is not only playing a role as ERα co-factor in breast cancer, but also has its own 
contribution to breast cancer progression such as repressing basal phenotype101, and 
cross-talk to ERBB2 signaling pathway102. Transient Foxa1 silencing results in a 
molecular profile transition toward basal phenotype and increases the in vitro 
aggressiveness of luminal breast cancer cells. Indeed, loss of Foxa1 may lead to growth 
arrest of a subpopulation of differentiated tumor cells, while the remaining cells may 
have greater chance to de-differentiate towards the basal phenotype. Foxa1 silencing 
may enrich this population, resulting in the observed shift toward the basal subtype.101 
This notion is supported by several studies based on MMTV-PyMT model: Elaine Y. 
Lin et al reported that MMTV-PyMT transgenic breast cancer model developed at late 
stage are characterized by decreased or loss of ERα and PR expression10;  and Kasi 
McCune et al further discovered tumor transition from luminal A subtype to luminal B 
subtype concomitant with decreased ERα and Foxa1 expression11. However, the 
underlying mechanisms of Foxa1 silencing are still unknown. 
 
In this study, we examined the endogenous Twist1’s function in breast cancer 
progression using a novel RCIP-TVA system-mediated tumor cell specific knockout of 
Twist1. We found that specific knock out of Twist1 in mammary gland tumor cells does 
not influence tumor initiation or growth but significantly decreased tumor EMT and 
metastasis. We also identified Foxa1 as a direct target of Twist1 in breast cancer. Twist1 
inhibits Foxa1 expression at transcriptional level and promotes breast cancer cell basal-
like phenotype, invasiveness and metastasis.  
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2. MATERIAL AND METHODS  
2.1 The TVA/RCIP system for induction of mouse mammary gland tumorigenesis 
with tumor cell-specific Twist1 knockout 
 
The Cre DNA fragment with a Not I and an Asc I sites was amplified by PCR, and a 
small IRES DNA fragment 103, 104 with an Asc I and a Pac I sites was chemically 
synthesized. These two fragments were cloned to the upstream of the PyMT-HA coding 
sequence through a Not I and a Pac I sites in the RCAS-PyMT avian-viral vector 105.  
The constructed RCAS-Cre-IRES-PyMT-HA (RCIP) vector was transfected into DF1 
cells to produce RCIP avian virus as described previously 105, 106.   The MMTV-TVA 
transgenic mouse line was described previously 105.  MMTV-TVA mice were crossbred 
with the ROSA26R Cre reporter mice 107, 108 to generate MMTV-TVA;ROSA26R bi-
genic mice.  MMTV-TVA mice were also crossbred with Twist1F/F mice obtained from 
Mutant Mouse Regional Resource Centers (016842-UNC) 63, 109 to generate MMTV-
TVA control (MMTV-TVA;Twist1+/+) and MMTV-TVA;Twist1F/F mice. All mice used 
in experiments were backcrossed at least for two generations in FVB strain background.  
PCR-based genotype analyses were carried out as described previously for the WT, 
floxed and deleted Twist1 alleles 109, the ROSA26R Cre reporter allele 107, 108 as well as 
the MMTV-TVA transgene 105.  PCR primers were listed in Supplemental Table S1.  For 
inducing mammary tumorigenesis, RCIP virus was intraductally introduced into the 4th 
mammary gland(s) of mice as described previously 105, 106.  The injected mice were 
closely examined for mammary tumor initiation by palpation, tumor growth by 
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estimating tumor volume, and distant metastasis by eye and microscopic examinations as 
described previously 68, 110.  Mice with mammary tumors were sacrificed 12 or 18 weeks 
after viral injection. Mice were euthanized according to the NIH guidelines. The animal 
protocols were approved by the IACUC of Baylor College of Medicine. 
 
2.2 Western blot  
 
Western blot was carried out as described previously 63, 111.  Briefly, 20 μg of protein in 
cell lysate was separated in SDS-PAGE gel and blotted onto a nitrocellulose membrane. 
After being blocked with phosphate-buffered saline containing 5% bovine serum 
albumin (BSA), the membrane was incubated with a primary antibody overnight at 4°C.  
These primary antibodies included antibodies against Twist1 (ab50887), Foxa1 
(ab23738), c-FOS (ab53036, Abcam, Cambridge, MA), E-cadherin (610182, BD 
Bioscience, San Jose, CA), VIMENTIN (5741), c-JUN (9165), HA (3724, Cell 
Signaling, Danvers, MA) and β-actin (Sigma, St Louis, MO).  Then, the membrane was 
washed 3 times in phosphate-buffered saline with Tween-20 (PBST) and incubated with 
horseradish peroxidase (HRP) conjugated secondary antibody (Bio-rad, Hercules, CA) 
for 1 hour.  In certain assays, the TrueBlot Western Blot Kit (eBioscience, San Diego, 
CA) with the secondary antibody was used to eliminate IgG bands according to the 
manufacture’s instruction.  Finally, the membrane was incubated with the SuperSignal 
West Pico Chemiluminescent Substrate (30479; Thermo Scientific, Rockford, IL) and 
imaged by exposing to X-ray films. 
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Western blot was carried out as described previously 63, 111.  Briefly, 20 μg of protein in 
cell lysate was separated in SDS-PAGE gel and blotted onto a nitrocellulose membrane. 
After being blocked with phosphate-buffered saline containing 5% bovine serum 
albumin (BSA), the membrane was incubated with a primary antibody overnight at 4°C.  
These primary antibodies included antibodies against Twist1 (ab50887), Foxa1 
(ab23738), c-FOS (ab53036, Abcam, Cambridge, MA), E-cadherin (610182, BD 
Bioscience, San Jose, CA), VIMENTIN (5741), c-JUN (9165), HA (3724, Cell 
Signaling, Danvers, MA) and β-actin (Sigma, St Louis, MO).  Then, the membrane was 
washed 3 times in phosphate-buffered saline with Tween-20 (PBST) and incubated with 
horseradish peroxidase (HRP) conjugated secondary antibody (Bio-rad, Hercules, CA) 
for 1 hour.  In certain assays, the TrueBlot Western Blot Kit (eBioscience, San Diego, 
CA) with the secondary antibody was used to eliminate IgG bands according to the 
manufacture’s instruction.  Finally, the membrane was incubated with the SuperSignal 
West Pico Chemiluminescent Substrate (30479; Thermo Scientific, Rockford, IL) and 
imaged by exposing to X-ray films. 
 
2.3 X-gal staining 
 
The RCIP virus-infected inquinal mammary glands of MMTV-TVA;ROSA26R mice 
were collected on day 3, 21 or 48 after the virus was introduced.  The mammary glands 
were slightly fixed and stained by X-gal as described previously 112.  The X-gal-stained 
mammary glands were further fixed in 4% paraformaldehyde (PFA), washed in 
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phosphate-buffered saline (PBS), dehydrated in ethanol and embedded in paraffin blocks 
as described 112.  Five-μm thick tissue sections were prepared and used for H&E 
staining. 
 
2.4 Cell culture  
  
DF1 chicken fibroblast cells, HEK293T human embryonic kidney cells and MCF7 
human breast cancer cells were cultured in MDEM medium containing 10% of fetal 
bovine serum (FBS).  BT549 cells were cultured in RPMI-1640 medium with 10% of 
FBS. SUM1315 cells were cultured in Hyclone Nutrient Mixture with 5% of FBS, 5 
µg/ml of insulin and 10 ng/ml of epidermal growth factor.  All cells were cultured at 
37°C in a tissue culture incubator supplied with 5% CO2. 
 
2.5 Circulating Tumor Cell (CTC) culture  
 
About one milliliter of blood sample was collected from each mouse with mammary 
gland tumors. CTCs were enriched by removing red blood cells using RBC lysis buffer 
(420301, Biolegend, San Diego, CA) according to the manufacture’s instruction. CTCs 
were cultured in MDEM medium containing 10% of fetal bovine serum (FBS) at 37°C 
in a tissue culture incubator supplied with 5% CO2 for 2 weeks. CTCs that form colonies 
which contain more than 10 cells were counted and colony numbers from two groups of 
mice were analyzed with student T-test.   
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2.6 H&E staining, immunohistochemistry (IHC) and immunohistofluorescence 
(IHF)   
 
Mammary tumors and/or lungs were dissected from euthanized MMTV-TVA;Twist1F/F 
and MMTV-TVA mice as well as SCID mice injected with MCF7Ctrl, MCF7Twist1 and 
MCF7Twist1+Foxa1 cells.  Isolated tissues were fixed overnight at 4°C in 4% PFA, washed 
in PBS, dehydrated in ethanol and embedded in paraffin blocks. Five-μm thick tissue 
sections were prepared and used for H&E staining, IHC and IHF as described previously 
63, 113.  Lung sections used for estimating metastasis extent were prepared as we 
described previously 77, 114.  For antibodies with a mouse origin, the M.O.M Mouse-on-
Mouse Immunodetection kit (Vector Laboratories, Burlingame, CA) was used to block 
the immunostaining background from the endogenous mouse IgG.  This study used the 
primary antibodies against Twist1 (ab50887), Foxa1 (ab23738, Abcam, Cambridge, 
MA), E-cadherin (610182, BD Bioscience, San Jose, CA), VIMENTIN (5741) and HA 
(3724, Cell Signaling, Danvers, MA).  The secondary antibodies for IHC were 
biotinylated anti-Rabbit IgG and biotinylated anti-mouse IgG (Vector Laboratories, 
Burlingame, CA), which were used at a 1:400 dilution.  The immunostaining signal was 
enhanced by using the VECTASTAIN ABC system (PK-6100, Vector Laoratories, 
Burlingame, CA), and then visualized by using the DAB kit (SK-4103, Vector 
Laoratories, Burlingame, CA).  The tissue slides were counterstained with Harris 
Modified Hematoxylin and mounted with Permount.  Double IHF was performed using 
the Tyramide Signal Amplification kit (Life technologies, Grand Island, NY) according 
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to the manufacturer's instructions. Stained tissue slides were examined and imaged under 
appropriate microscopes.  Tumor and lung areas in the lung images were measured by 
using the NIH ImageJ software as described previously 77, 114. 
 
2.7 Quantitative RT-PCR (qPCR)   
 
Total RNA was isolated from WT/RCIP and Twist1TKO/RCIP mammary tumors and 
BT549, Sum1315, MCF7, MCF7Ctrl, MCF7Twist1 and MCF7Twist1+Foxa1 cells using the 
TRIZOL reagent (Life technologies, Grand Island, NY).  Reverse transcription was 
performed with 1 μg of RNA by using the Reverse Transcriptase Core kit (Eurogentec; 
Fremont, CA).  qPCR was performed by using the matched Universal Taqman probes 
(Roche, Nutley, NJ) and gene-specific primer pairs (Table 2.1). The measurement of 18 
S or β-actin mRNA was used as an endogenous normalizer. 
 
2.8 Genomic DNA extraction from paraffin embedded samples 
 
Genomic DNA was isolated from lung paraffin sections of both groups of mice using 
QIAamp DNA FFPE Tissue Kit (56404, Qiagen, Hilden, Germany). The genomic DNA 
was used for PCR analysis of the Twist1 gene knockout allele. 
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2.9 Micro-vascular density calculation 
 
Microvascular density was determined as described previously115. In brief, blood vessels 
were visualized by CD31 immunohistochemistry in the tissue sections prepared from 
mouse tumors. Tumor areas which contain greatest vessel density were defined as hot 
spots regions. Images of hot spots regions were taken under a microscope at 200× 
magnification. Any stained endothelial cells were counted to represent a single vessel if 
it was clearly separated from adjacent microvessels and other connective tissue 
elements.  
 
2.10 Plasmids and cell transfection   
 
For constructing the Foxa1-Luc promoter-reporter plasmid, the 1.5 kb 5’ regulatory 
sequence of the human Foxa1 gene was amplified by PCR using specific primers 
(Supplemental Table S1) from the gemomic DNA of MCF7 cells and subcloned into the 
Kpn I and Nco I sites of the pGL3-basic-luciferase plasmid.  The human E-cadherin-Luc 
and CSF1-Luc plasmids were described previously 68, 106.  The pCDNA-Twist1-2×flag 
expression plasmid was constructed by subcloning human Twist1 cDNA into the 
pCDNA-2×flag plasmid.  The pCDH-Foxa1 plasmid was a gift from Dr. Bin He at 
Baylor College of Medicine.  
 
For assaying the activity of a promoter-reporter construct, MCF7 cells were transfected 
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with the expression vectors and promoter-luciferase reporter plasmid as indicated in the 
Results section using the polyethylenimine reagent (23966-2, Polyscience, Niles, IL) 116.  
The transfected cells were harvested 24 hours and lysed with the Reporter Lysis buffer 
(Promega, Madison, WI) for luciferase assay as described 106.  The relative luciferase 
activity was normalized to the total amount of protein assayed.  
 
To generate MCF7Twist1 cell lines, MCF7 cells were transfected with pCDNA-2×flag and 
pCDNA-Twist1-2×flag plasmids using the Polyethylenimine reagent.  Transfected cells 
were cultured in DMEM medium containing 2 µg/ml of Hygromycin for 2 weeks.  To 
generate MCF7Twist1+Foxa1 cell lines, two MCF7Twist1 cell lines were transfected with 
pCDH-Foxa1 plasmid and growth-selected for 14 days in DMEM medium containing 4 
µg/ml of Puromycin.  The surviving colonies in each experiment were individually 
isolated, expanded in growth medium and analyzed by Western blot. 
 
In siRNA-based knocking down experiments, non-targeting control siRNAs and siRNAs 
targeting human Twist1 and c-Fos mRNAs were purchased from Dharmacon (Lafayette, 
CO).   BT549, Sum1315 and MCF7 cells were transfected with siRNAs using the 
HiPerFect Transfection Reagent (301705, QIAGEN, Valencia, CA). 
  
Knockdown of Twist1 mRNA by stable expression of shRNAs: pGIPZ-shCtrl lentiviral 
vector coding for a non-targeting shRNA (5’-CTTACTCTCGCCCAAGCGAGAG) and 
2 pGIPZ-shTwist1 lentiviral vectors coding for two different Twist1 mRNA-targeting 
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sequences (TGAATGCATTTAGACACCG and AGAGGAAGTCGATGTACCT) were 
obtained from the Cell-Based Assay Screening Service Core at Baylor College of 
Medicine. Lentivirus was packaged in 293T cells transfected with pMD2.G, psPAX2, 
and pGIPZ shRNA vectors in the ratio of 1:3:4. The culture medium was refreshed 6 
hours after transfection. 24 hours after transfection, the medium containing viral 
particles was collected and polybrene was added to a concentration of 4 µg/ml for 
infecting cells. SUM1315 and MDA-MB-436 cells were infected with the prepared viral 
particles and selected in the culture medium containing 1 µg/ml of puromycin for 10 
days. Survived cells were expanded and used for experimental analysis. 
 
2.11 ChIP assay   
  
The DNA-bound proteins in BT549, Sum1315, MCF7Ctrl and MCF7Twist1 cells were 
cross-linked using 1% formaldehyde for 10 minutes.  ChIP assays were performed as 
described previously 68, 106. Antibodies used in these ChIP assays were for Twist1 
(ab50887), c-JUN (ab31419, Abcam, Cambridge, MA), MTA2 (28791), HDAC2 
(7899x, Santa Cruz, Dallas, TX), c-FOS (2250, Cell Signaling, Danvers, MA), Histone 
H3K9ac (39585, Active motif, Carlsbad, CA), RNA pol II (PLA0127, Sigma-Aldrich, 
St. Louis, MO) and M2 Flag antibody beads (A2220, Sigma-Aldrich, St. Louis, MO).  
ChIP-grade mouse IgG and rabbit IgG (Abcam, Cambridge, MA) were used as negative 
controls.  The sequences of PCR primers used for amplifying the precipitated DNA 
samples are listed in Table 2.1. 
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2.12 Cell migration and invasion assays   
 
Cell migration and invasion capabilities were measured as described previously 78.  
Briefly, individual cell migration was directly traced in a 96-well plate for 18 hours 
using the Cell Motility HCS Reagent kit (K08-000-11, Thermo Scientific, Rockford, IL).  
The track areas on the electronic images were quantitatively measured using the Image J 
software.  Cell invasion was assayed by using BioCoat Matrigel Invasion Chambers (BD 
Biosciences, San Jose, CA).  A total of 25,000 cells were seeded in each upper chamber 
with serum-free DMEM medium and the lower chamber was filled with DMEM 
containing 5% FBS. After cultured for 24 hours, non-migrating cells on the upper 
chambers were removed by a cotton swab, and cells invaded through the Matrigel layer 
to the underside of the membrane were stained with crystal violet and counted. 
 
2.13 In vivo metastasis assay  
 
MCF7Ctrl, MCF7Twist1 or MCF7Twist1+Foxa1 cells (1x106) were injected into 8-week-old 
female SCID mice through the tail vein. These mice were sacrificed in 4 weeks after the 
injection. Their lung tissues were collected, photographed and processed for paraffin 
section. Metastasis was evaluated by counting the visible metastatic foci on the lung 
surface and measuring metastasis tumor area versus the lung area on H&E-stained lung 
sections as described previously 77, 114. 
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2.14 Statistical analyses   
 
All data were collected from several independent experiments. Each assay was 
performed in triplicate whenever applicable. All data were expressed as Mean ± SEM. 
Prism 4 Software (GraphPad, La Jolla, CA) was used to perform Student’s t test to 
analyze the data sets of mRNA level, tumor volume, luciferase activity, cell migration 
and invasion, metastatic tumor number and index.  Log-rank test was used to analyze the 
data sets of mouse tumor-free survival and human breast cancer patient DMFS. Fisher’s 
exact test was used to analyze the data sets of Foxa1 IHC scores. Person’s Correlation 
test was used to analyze the Twist1 and Foxa1 expression data sets.  In all statistical 
analyses, p < 0.05 was considered significant. 
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Oligo Names Sequences TaqMan Probe # 
Twist1 genotyping 112  agcggtcatagaaaacagcc N/A 
Twist1 genotyping 114 ccggatctatttgcattttaccatgggtca tc N/A 
Twist1 genotyping 115 cctctacctgaccgttagatggactcgg N/A 
TVA genotyping F ctgctgcccggtaacgtgaccgg N/A 
TVA genotyping R gccctggggaaggtcctgccc N/A 
Mouse Twist1 F agctacgccttctccgtct 58 
Mouse Twist1 R tccttctctggaaacaatgaca 58 
Mouse Foxa1 F gaacagctactacgcggaca 82 
Mouse Foxa1 R cggagttcatgttgctgaca 82 
Mouse 18S F ctcaacacgggaaacctcac 77 
Mouse 18S R cgctccaccaactaagaacg 77 
Mouse ACTB F ctaaggccaaccgtgaaaag 64 
Mouse ACTB R accagaggcatacagggaca 64 
Human Twist1 F gggccggagacctagatg 50 
Human Twist1 R tttccaagaaaatctttggcata 50 
Human Foxa1 F cccctttgtcctctctaccc 81 
Human Foxa1 R ctgcaaagcaagaagcagagt 81 
Human c-Fos F actaccactcacccgcagac 67 
Human c-Fos R ccaggtccgtgcagaagt 67 
Human MMP9 F tcttccctggagacctgaga 27 
Human MMP9 R gagtgtaaccatagcggtacagg 27 
Human ITGA5 F ccgtgtggttttaggtggac 68 
Human ITGA5 R ttgatcaggtactcggggtaa 68 
Human ITGAv F catgtcctccttatacaattttactgg 46 
Human ITGAv R gcagctacagaaaatccgaaa 46 
Human ITGB1 F caagttgcagtttgtggatca 66 
Human ITGB1 R agtgaaacccggcatctg 66 
Human ITGB3 F gcaagatcacgggcaagta 2 
Human ITGB3 R ggagtcacacaggcagtcc 2 
Human ACTB F attggcaatgagcggttc 11 
Human ACTB R cgtggatgccacaggact 11 
Human 18S F gaggccgtaggcttattgtg 11 
Human 18S R gagtagctcatatgtcttccctacct 11 
Human CSF1 ChIP F ctttcggcactccgagaat N/A 
Human CSF1 ChIP R tccaggctgattcagtgcta N/A 
Human CDH1 ChIP F ccaagtgtaaaagccctttctg N/A 
Human CDH1 ChIP R ttgctagggtctaggtgggtta N/A 
Human Foxa1 ChIP 5k F agtaggggaaaagacaaacccagt N/A 
Human Foxa1 ChIP 5k R gcttgtgtctgtgtgtctttgtgt N/A 
Human Foxa1 ChIP 4k F cctgctaaataggaaggaccctgt N/A 
Human Foxa1 ChIP 4k R gatattcaccaggcaggtagaagc N/A 
Human Foxa1 ChIP 3k F catcacgctatgaaaagtggattt N/A 
Human Foxa1 ChIP 3k R caaatgttcttttagcccacttcc N/A 
Human Foxa1 ChIP 2k F gcagtacaacaaacacatggtcac N/A 
Human Foxa1 ChIP 2k R gttggtgatagattgggagatggt N/A 
Human Foxa1 ChIP 1k F gtgctgtgactcacctgctcttag N/A 
Human Foxa1 ChIP 1k R ccacttttgcttcgtcactagaaa N/A 
Human Foxa1-Luc F tgggtaccgtccaggaccgattaggaacc N/A 
Human Foxa1-Luc R gcccatggatacaaccatccagccctgtg N/A 
Table 2.1. Oligonucleotide primers and probes for PCR 
  38
3. RESULTS* 
 
3.1 A new mouse model system for simultaneous deletion of the floxed alleles and 
expression of an oncogene in a subset of the mouse mammary epithelial cells 
  
Du et al. has previously generated MMTV-TVA mouse line, in which the transgene for 
the tva avian virus subgroup A receptor is driven by MMTV (mouse mammary tumor 
virus) promoter and specifically expressed in the mammary gland luminal epithelial cells 
105. Intraductal instillation of the avian leukosis virus RCAS (replication-competent 
avian sarcoma-leukosis virus LTR splice acceptor) carrying PyMT caused the infection 
of a small subset of the TVA-expressing mammary epithelial cells in MMTV-TVA 
mice, resulting in rapid mammary tumorigenesis 105. In order to inactivate a floxed gene 
of interest in the mammary tumor cells induced by the MMTV-TVA/RCAS-PyMT 
system, we constructed the RCAS-Cre-IRES-PyMT (RCIP) vector (Fig. 3.1A) and 
generated RCIP avian virus with this vector. Western blot analysis revealed that both 
Cre and PyMT proteins were expressed in the RCIP virus-infected DF1 cells but not in 
the RCAS control virus-infected DF1 cells (Fig. 3.1B). These results demonstrate that 
the RCAS promoter is strong enough to drive both Cre and PyMT protein expression 
after the viral DNA is integrated into the cell genome. 
                                                 
* Part of the data reported in this section is reprinted from “Twist1 Promotes Breast 
Cancer Invasion and Metastasis by Silencing Foxa1 Expression” by Yixiang Xu et al, 
2016. Oncogene, Epub ahead of print. Yixiang Xu retains the copyright of the article as 
stated on the publisher’s website. 
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Next, we generated MMTV-TVA;ROSA26R bi-genic mice by crossbreeding MMTV-
TVA and ROSA26R mice  and injected RCIP avian virus into the mammary gland ducts 
of these mice. The ROSA26R locus contains a floxed transcriptional STOP sequence 
that silences the -galactosidase (-gal) expression and thus, serves as a reporter for Cre 
activity 107, 108. The mammary glands were isolated on the 3rd, 21st and 48th days post 
viral injection and analyzed by X-gal staining and histopathological examination (Fig. 
3.1C).  In the virus-injected mammary glands of MMTV-TVA;ROSA26R female mice, 
individually scattered -gal-positive mammary gland epithelial cells were detected by 
day 3.  One to multiple epithelial hyperplasia lesions consisting of only the -gal-
positive cells were developed by day 21 and invasive mammary gland tumors with -
gal-positive cells were formed by day 48 (Fig. 3.1D).  Double immunofluorescent 
staining revealed that both PyMT and -gal proteins were co-expressed in these tumor 
cells, indicating these tumor cells were derived from RCIP virus-infected mammary 
epithelial cells and Cre expressed in these cells worked effectively (Fig. 3.1E).  In 
contrast, no -gal-positive or PyMT-positive mammary epithelial cells or tumor cells 
were observed in the MMTV-TVA;ROSA26R mouse mammary glands without viral 
injection or in the ROSA26R mouse mammary glands with injection of RCIP virus (data 
not shown).  These results demonstrate that the MMTV-TVA/RCIP (hereafter 
designated as TVA/RCIP) system is fully capable to express both Cre and an oncogene 
in the same mammary epithelial cells for simultaneous and effective deletion of a floxed 
gene and induction of tumorigenesis. 
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Figure 3.1. The mammary tumorigenesis mouse model induced by the novel 
MMTV-TVA/RCIP system.  A. The RCAS-Cre-IRES-PyMT-HA (RCIP) vector of the 
avian virus.  B. Detection of both Cre and PyMT-HA proteins in the RCIP vector-
transfected DF1 cells by Western blotting, while these proteins were not present in the 
untransfected DF1 (Ctrl) cells.  C. The strategies to induce β-gal-labeled mammary 
tumors in the female MMTV-TVA;ROSA26R mice by using the RCIP system.  D. X-gal 
staining to show RCIP virus-infected and induced mammary tumor cells (blue color) in 
the mammary glands of MMTV-TVA;ROSA26R mice after intraductal injection of 
RCIP virus for 3, 21 and 48 days.  E. Double immunofluorescence (IF) staining for 
PyMT-HA (red) and β-gal (green) in a RCIP-induced mammary tumor isolated from 
MMTV-TVA;ROSA26R mice.  A section of a mammary gland isolated from a normal 
female mouse served as a negative control for HA and β-gal IF staining. 
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3.2 Tumor specific knock-out of Twist1 using TVA/RCIP system in Twist1-floxed 
mice 
 
To knockout Twist1 in PyMT-induced mammary tumor cells by using TVA/RCIP 
system, we generated female MMTV-TVA and MMTV-TVA;Twist1F/F mice with the 
same strain background by crossbreeding MMTV-TVA and the floxed Twist1 (Twist1F/F) 
mice 63, 105, 109.  To get Twist1TKO/RCIP tumors (RCIP-induced tumors with tumor cell-
specific Twist1 knockout), we injected RCIP virus into the ductal lumens of either one or 
two of their 4th mammary glands, when MMTV-TVA;Twist1F/F mice were 8 weeks old. 
PyMT oncogene induces tumorigenesis only in the Twist1 knockout mammary epithelial 
cells (Fig. 3.2A).  MMTV-TVA mice were used as control group to get WT/RCIP 
tumors. 
 
To evaluate Twist1 knockout efficiency, we prepared genomic DNA, RNA and protein 
samples from RCIP virus-induced mammary tumors, and performed genotype, Q-PCR 
and Western blot analyses.  As expected, genotype analysis only detected wild type 
Twist1 allele in WT/RCIP tumors, but detected both the deleted and the floxed Twist1 
alleles in Twist1TKO tumors due to the presence of both the tumor cells with Twist1 
deletion and the non-tumor cells with the floxed Twist1 in the tumor tissues (Fig. 3.2B).  
Q-PCR analysis detected a 14-fold decrease in Twist1 mRNA expression in 
Twist1TKO/RCIP tumors compared with WT/RCIP tumors (Fig. 3.2C). Western blot 
analysis revealed a significant reduction of Twist1 protein in Twist1TKO/RCIP tumors 
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versus WT/RCIP tumors (Fig. 3.2D). We further performed immunostaining and 
confirmed that variable levels of Twist1 protein was expressed in a sub-population 
(~6%) of tumor cells and certain stromal cells in WT/RCIP tumor tissues, but Twist1 
protein was only detected in the stromal cells in Twist1TKO/RCIP tumor tissues.  
Moreover, Twist1 and PyMT-HA double positive tumor cells were observed in 
WT/RCIP tumors, while only PyMT-HA single positive tumor cells were seen in 
Twist1TKO/RCIP tumors (Fig. 3.2E).  These results demonstrate that Twist1 is expressed 
in a subset of mammary tumor cells and certain stromal cells in WT/RCIP tumors, while 
in Twist1TKO/RCIP tumors Twist1 was completely knocked out in the tumor cells but 
normally expressed in the infiltrating stromal cells. 
 
 
  43
 
Figure 3.2. Mammary tumor cell-specific knockout of Twist1 in mice. A. 
Experimental strategies to induce mammary tumors with and without TKO of Twist1 
using the MMTV-TVA/RCIP system.  TVA, MMTV-TVA mice; WT, wild type mice.  
B. PCR-based analysis of the wild type (WT), floxed (Twist1F) and Cre-deleted 
(Twist1TKO) Twist1 alleles in WT/RCIP and Twist1TKO/RCIP mouse mammary tumors.  
C. Q-PCR-based analysis of Twist1 mRNA in WT/RCIP and Twist1TKO/RCIP mouse 
mammary tumors.  Data are presented as Mean ± SEM.  D. Western blot analysis of 
Twist1 protein in WT/RCIP (n=4) and Twist1TKO/RCIP (n=4) mammary tumors.  The β-
actin served as an endogenous loading control.  The mouse IgG band was recognized by 
the secondary antibody.  E. Detection of Twist1 (brown) by IHC in both tumor and 
stromal cells in WT/RCIP tumors but only in stromal cells in Twist1TKO/RCIP tumors 
(upper panels). In lower panels, double IF staining detected Twist1 (arrowheads) in 
PyMT-HA-expressing tumor cells in WT/RCIP tumors, but no Twist1 in PyMT-HA-
expressing tumor cells in Twist1TKO/RCIP tumors.  Scale bars, 50 µm. 
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3.3 Specific ablation of Twist1 in the PyMT-induced mammary tumor cells does not 
affect primary tumor development in mice 
Palpable mammary tumors were detected in both genotype groups of mice within 6-10 
weeks after viral injection, showing no difference in the latency of tumor initiation 
between MMTV-TVA;Twist1F/F and MMTV-TVA mice (Fig. 3.3 A). Thirty-five and 26 
tumors were developed from 60 virus-infected mammary glands in MMTV-
TVA;Twist1F/F mice and 42 virus-infected mammary glands in MMTV-TVA mice, 
respectively.  The tumorigenic rate was about 60% for both groups.  These results 
indicate that specific inactivation of Twist1 in the mammary epithelial cells does not 
affect PyMT-induced mammary tumor formation. 
We measured tumor growth for 10 weeks after a palpable tumor was detected in the 
RCIP virus-infected mammary gland of MMTV-TVA;Twist1F/F or MMTV-TVA mice. 
The tumor growth data was only collected from mice bearing a single tumor. We found 
that the average tumor growth rates in the two groups of mice were very similar (Fig. 
3.3B).  Cell proliferation rates assayed by Ki67 immunohistochemistry also showed no 
significant difference between Twist1TKO/RCIP mammary tumors isolated from MMTV-
TVA;Twist1F/F mice and WT/RCIP mammary tumors (RCIP-induced tumors with wild 
type Twist1)  isolated from MMTV-TVA mice (Fig. 3.4A).  Analysis of cell apoptosis 
by cleaved-caspase 3 staining and macrophage recruitment by F4-80 staining also 
revealed no difference between these two groups (Fig. 3.4 B&C). These results indicate 
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that the autonomous cellular function of Twist1 is not required for the growth of PyMT-
induced mammary tumors in mice. 
Figure 3.3. Tumor cell-specific knockout (TKO) of Twist1 does not influence tumor 
initiation or growth in mice. A. Tumor-free survival curves for WT/RCIP (RCIP-
infected MMTV-TVA mice) and Twist1TKO/RCIP (RCIP-infected MMTV-
TVA;Twist1F/F mice) mice. Mammary tumor development was monitored by palpation. 
B. WT/RCIP and Twist1TKO/RCIP mammary tumor growth curves generated by 
measuring tumor volumes (Vol.) once a week after palpable tumors were detected.  
3.4 Specific ablation of Twist1 in the PyMT-induced mammary tumor cells inhibits 
lung metastasis 
Next, we examined lung metastasis in the RCIP virus-infected MMTV-TVA 
and MMTV-TVA;Twist1F/F mice in which a palpable tumor had grown for 10 
weeks.  We observed lung metastases in 67% (12/18) of MMTV-TVA mice 
with 5.38 metastatic foci/lung in average number.  However, we only observed 
lung metastases in 39% (7/18) of MMTV-TVA;Twist1F/F mice with 0.38 
metastatic foci/lung in average (Fig. 3.5A). On the lung tissue sections, the 
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Figure 3.4 IHC staining of primary tumors.  A. Representative images of Ki67 IHC 
on WT/RCIP and Twist1TKO/RCIP primary tumor sections and the quantification of 
staining result. B. Representative images of c-Caspase3 (cleaved caspase3) IHC on 
WT/RCIP and Twist1TKO/RCIP primary tumor sections and the quantification of staining 
result. C. Representative images of F4-80 IHC on WT/RCIP and Twist1TKO/RCIP 
primary tumor sections and the quantification of staining result. 
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average percentage of metastasis area to total lung area, which is an index for 
metastasis extent, was also drastically reduced in MMTV-TVA;Twist1F/F mice 
versus MMTV-TVA mice (Fig. 3.5B).  These results demonstrate that Twist1 null 
mammary tumor cells have a drastically decreased metastasis capability compared with 
Twist1 WT mammary tumor cells. 
Figure 3.5. Tumor cell-specific knockout (TKO) of Twist1 inhibits lung metastasis 
in mice. A.The images of lungs isolated from MMTV-TVA/RCIP and MMTV-
TVA;Twist1F/F/RCIP mice bearing palpable mammary tumors for 10 weeks (upper 
panels).  Arrowheads indicate metastasis foci observed on the lung surface. The numbers 
of metastasis foci observed in the sections of individual lungs of both mouse groups are 
presented in the lower panel.  B. H&E-stained lung sections of mice with WT/RCIP 
and Twist1TKO/RCIP mammary tumors for 10 weeks.  Arrowheads indicate metastasis 
foci (upper panels).  Metastasis index was presented as the average percentage of 
metastasis tumor areas to total lung areas measured on the electronic images 
recorded from H&E-stained lung sections.  Scale bars, 100 µm.  
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We also performed Ki67 immunostaining and found higher proliferating ratio in 
MMTV-TVA;Twist1F/F mice metastasis tumors than in MMTV-TVA mice metastasis 
tumors (Fig. 3.6A).  This result suggests that the reduced metastasis of Twist1 null tumor 
cells in MMTV-TVA;Twist1F/F mice was not caused by any decrease in tumor cell 
proliferation in the lung.  Instead, the lung metastasis may happen at a later stage in 
MMTV-TVA;Twist1F/F mice versus MMTV-TVA mice.  
We isolated genomic DNA from lung paraffin section with metastasis foci. Genotype 
analysis showed wild type Twist1 allele is only detected in WT/RCIP groups and floxed 
allele is only detected in Twist1TKO group (Fig. 3.6B). However, deleted Twist1 alleles 
were detected in some Twist1TKO lungs, suggesting that Twist1 null tumor cells could 
also metastasize to lung but have a drastically decreased metastasis capability compared 
with Twist1 WT mammary tumor cells. 
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Figure 3.6. Ki67 staining and genomic DNA PCR of metastasis tumors. A. 
Representative images of Ki67 IHC on WT/RCIP and Twist1TKO/RCIP lung metastasis 
sections and the quantification of staining result. B. PCR-based analysis of the wild type 
(WT), floxed (Twist1F) and Cre-deleted (Twist1TKO) Twist1 alleles and tumor marker 
PyMT in WT/RCIP and Twist1TKO/RCIP mouse lung sections with metastasis foci.   
 
 
 
3.5 Specific ablation of Twist1 in the PyMT-induced mammary tumor cells inhibits 
EMT and invasiveness 
 
Cell line based studies showed that Twist1 promotes EMT, angiogenesis and local 
invasiveness. Thus, we examined EMT status of both Twist1TKO/RCIP and WT/RCIP 
tumors by triple fluorescent IHC staining of Twist1/PyMT-HA/E-cadherin or 
Twist1/PyMT-HA/Vimentin. We found that Twist1 positive tumor cells (Twist1/PyMT-
HA double positive) showed increased Vimentin expression and decreased E-cadherin 
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expression compared with Twist1 negative tumor cells in WT/RCIP tumor sections (Fig. 
3.7A and B). On the other hand, we did not see any Twist1 positive tumor cells from the 
Twist1TKO/RCIP tumor sections.  However, we did see a few Twist1 negative tumor cells 
from both groups showed decreased E-cadherin or increased Vimentin (Fig. 3.7 A and 
B), suggesting that Twist1 is not the only regulator of EMT in the tumor cells. 
Quantification of the staining showed there are about 9.0 % Vimentin positive tumor 
cells and about 45% of which are Twist1 positive in WT group. In Twist1TKO/RCIP 
tumors, about 2.6% of tumor cells are Vimentin positive. Vimentin and E-cadherin 
expression levels in Twist1 positive and negative tumor cells in WT/RCIP group were 
scored in a scale of 0-3 (0 means negative/non-detectable while 3 means strong 
expression). Twist1 positive tumor cells showed significant higher Vimentin score but 
lower E-cadherin score. These data suggest that Twist1 is a master inducer of EMT in 
the mouse mammary gland tumors. 
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Figure 3.7. Vimentin and E-cadherin expression in Twist1 positive and negative 
tumor cells. A. IF staining of Vimentin, PyMT-HA and Twist1 in WT/RCIP and 
Twist1TKO/RCIP mammary tumors. Vimentin expression level in Twist1 positive tumor 
cells and Twist1 negative tumor cells were scored and shown in right panel. B. IF 
staining of E-cadherin, PyMT-HA and Twist1 in WT/RCIP and Twist1TKO/RCIP 
mammary tumors. E-cadherin expression level in Twist1 positive tumor cells and Twist1 
negative tumor cells were scored and shown in right panel. Scale bar, 50 µm. 
 
Micro-vascular density is an important marker for invasiveness, thus we performed 
CD31 IHC on both Twist1TKO/RCIP and WT/RCIP tumor sections. Knockout of Twsit1 
in tumor cells significantly decreased Micro-vascular density by around 50% (Fig. 
3.8A). Consistent with the active EMT and angiogenesis promoted by Twist1, we 
detected more circulating tumor cells (CTCs) from the blood of mice with WT/RCIP 
tumors compared with those mice with Twist1TKO/RCIP tumors (Fig. 3.8B). Taken 
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together, Twist1 promotes EMT and angiogenesis to facilitate primary mammary gland 
tumor cell invasiveness and intravasation into the blood circulation. 
 
Figure 3.8. TKO of Twist1 in the PyMT-induced mammary tumor cells inhibits 
angiogenesis and invasion in to blood circulation. A. Micro-vascular density of 
WT/RCIP and Twist1TKO/RCIP mouse mammary tumors. B. Circulating tumor cells 
(CTCs) colony culture from mice with WT/RCIP or Twist1TKO/RCIP mammary tumors. 
 
 
 
3.6 Twist1 expression is turned off in lung metastasis foci 
 
To figure out Twist1’s role in metastasis tumors, we examined Twist1 expression in lung 
metastasis foci. Interestingly, double staining of Twist1 and tumor marker PyMT-HA 
showed that metastasis foci do not expression Twist1 protein in either WT/RCIP or 
Twist1TKO/RCIP groups (Fig 3.9A). This phenotype is consistent with the previous report 
that Twist1 is turned off in metastasis tumors through MET49. We then performed 
double staining of PyMT-HA with E-cadherin or Vimentin and found that all metastasis 
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tumor cells are E-cadherin positive but Vimentin negative.  Double staining of E-
cadherin and Vimentin also showed no overlapping, further supports the conclusion that 
Twist1 is turned off in the metastasis foci and metastasis tumor showed epithelial 
phenotype. (Fig. 3.9B, C and D).  
 
3.7 Twist1 is expressed at late tumor stage and is associated with reduced ER 
and Foxa1 expression in mouse tumors 
 
Above data showed that Twist1 was non-essential in early stage of tumor progression, 
however, it was unclear whether Twist1 is expressed but does not contribute to early 
stage tumor progression or it is not expressed at all. Thus we examined Twist1 protein 
expression by IHC in both groups of tumors at early stage (6weeks after tumor became 
palpable, volume ≈ 0.5 cm3) and late stage (10 weeks after tumor became palpable, 
volume ≈ 1.0 cm3). Interestingly, we found no Twist1 immunoreactivity was detected in 
the early stage tumor cells, while ERα protein was detected at high levels in both tumor 
cells and non-tumor mammary epithelial cells (Fig. 3.10A). In late stage tumors, about 
6% of WT/RCIP tumor cells express Twist1, suggesting that Twist1 mainly functions at 
late stage. 
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Figure 3.9. Twist1, Vimentin and E-cadherin expression in lung metastasis tumor 
foci of WT/RCIP and Twist1TKO/RCIP groups. A. IF staining of Twist1 and PyMT-
HA in lung metastasis foci of both groups. B. IF staining of E-cadherin and PyMT-HA 
in lung metastasis foci of both groups. C. IF staining of Vimentin and PyMT-HA in lung 
metastasis foci of both groups. D. IF staining of E-cadherin and Vimentin in lung 
metastasis foci of both groups. 
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Figure 3.10. Twist1, ERα and Foxa1 IHC in mouse tumors and IRS score. A. IHC 
for Twist1 ERα and Foxa1 (brown) in WT/RCIP and Twist1TKO/RCIP mammary tumors 
at 6 and 10 weeks after becoming palpable in mice.  B. The sample distribution and 
Fisher’s Exact test of ERα ( strong positive (IRS>4) and weak positive or negative (IRS 
≤ 4)) and Foxa1 (negative (IRS=0) and positive (IRS>0)) in WT/RCIP and 
Twist1TKO/RCIP mouse mammary tumors at 10 weeks after becoming palpable in mice.   
As a semi-quantitative analysis, we evaluated the immunoreactivity scores (IRS) of ERα 
and Foxa1 in both groups of tumors using the Allred Scoring System 117. In late stage 
tumors ERα immunoreactivity was drastically decreased compared with that detected in 
the early stage (20% vs 58% positivity). Interestingly, although ERα was also reduced in 
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most of the tumor cells of late stage Twist1TKO/RCIP tumors compared with early stage, 
there were still 59% of tumor cells expressing detectable ERα and 14% of tumor cells 
expressing high level ERα. As an ERα co-activator and a determinant of ERα signaling 
in breast cancer, Foxa1 protein showed similar expression pattern as ERα. Foxa1 was 
detected at high levels in both tumor cells and non-tumor mammary epithelial cells at 
early stage (Fig. 3.10A).  However, Foxa1 immunoreactivity was very weak (12%) or 
negative (71%) in WT/RCIP tumor cells, while there were still 71% of tumor cells with 
detectable Foxa1 and 8% of tumor cells with high level Foxa1 in large Twist1TKO/RCIP 
tumor group. Using Allred Scoring System, we found that late stage tumors are still ERα 
positive (IRS > 2, as generally accepted for determining positivity of ERα in human 
breast cancer patients), thus we compared ERα strong positive (IRS>4) to ERα weak 
positive or negative (IRS ≤ 4) ratios in the two groups of tumors and found that 
Twist1TKO/RCIP tumors are all ERα strong positive while more than 50% of WT/RCIP 
tumors turn to ERα weak positive or negative (Fig. 3.10B left panel). On the other hand, 
Foxa1 expression level is low in both groups of tumors, thus we compared Foxa1 
negative (IRS = 0) to Foxa1 weak or strong positive (IRS > 0) ratios between the two 
groups. As shown in the right panel of Fig. 3.10B, the ratio of Foxa1-positive tumors 
was significantly higher in Twist1TKO/RCIP tumor group versus WT/RCIP tumor group. 
Together, these results demonstrate that the level of Twist1 expression negatively 
correlates with the level of ERα and Foxa1 expression in the PyMT-induced mouse 
mammary tumors. ERα has been shown to be a direct target of Twist1 in human breast 
cancer cells, thus we next investigated whether and how Foxa1 is regulated by Twist1. 
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3.8 Twist1 expression inversely associates with Foxa1 expression in human 
breast cancer 
Based on the mouse tumor IHC result, we hypothesized that Twist1 inhibits Foxa1 
expression to promote breast cancer invasiveness. To identify whether this regulation is 
true in human breast cancer, we analyzed a dataset deposited in the NCBI GEO database 
(GSE53222) 85 and found that Twist1 expressed in the T47D ER-positive breast cancer 
cells decreased the expression of a group of luminal epithelial genes including Foxa1, 
ESR1, PRLR, PGR, MUC1 and CLDN3 (Fig. 3.11), further supporting the hypothesis 
that Foxa1 is target of Twist1 in breast cancer.   
Figure 3.11. Downregulated genes by Twist1 overexpression in T47D human breast 
cancer cells. Several known luminal type breast cancer marker genes are downregulated 
by Twist1 overexpression, including Foxa1, ESR1, GATA3, MUC1. (Data source: Shi J 
et al, Cancer Cell, 201485 ) 
We further analyzed the correlation between the expression levels of Twist1 and Foxa1 
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mRNAs in human breast cancer using another dataset from 281 human breast tumors in 
NCBI GEO (GSE2034) 118.  This analysis also revealed a significant negative correlation 
between the levels of Twist1 and Foxa1 mRNA expression (Fig. 3.12A).  We also 
analyzed the correlation between the expression levels of Twist1 and Foxa1 mRNAs in 
luminal and basal subtype human breast cancer cell lines by using GEO2R software and 
a dataset in the NCBI GEO database (GSE15361) 119.  Among 44 breast cancer cell lines 
with RNA-profiling data, the level of Twist1 mRNA negatively correlated with the level 
of Foxa1 mRNA (Fig. 3.12D).  The average level of Twist1 mRNA was significantly 
higher in basal-like breast cancer cell lines compared with luminal type of breast cancer 
cell lines (Fig. 3.12B).  In contrast, the average level of Foxa1 mRNA was significantly 
lower in basal-like breast cancer cell lines compared with luminal type of breast cancer 
cell lines (Fig. 3.12C).  To validate these data at protein levels, we performed Western 
Blot for Twist1 and Foxa1 in a group of breast cancer cells lines. We found that Twist1 
is highly expressed in basal-like breast cancer cell lines, while Foxa1 is exclusively 
expressed in luminal type breast cancer cell lines. We further analyzed a cohort of 276 
human breast tumors by IHC staining of both Twist1 and Foxa1.  Twist1 protein was 
detected in 13 out 276 (5%) tumors and Foxa1 is detected in 94% tumors (245 out of 
261), indicating that this cohort mainly consists of luminal breast tumors. Interestingly, 
179 out of 261 (68.6%) tumors showed very high (>6) Foxa1 immunoreactive scores 
(IRSs). However, the 13 Twist1-positive tumors had IRSs of 6 or lower. The 
immunoreactive scores of Twist1 and Foxa1 and the ER, PR and HER2 expression 
profiles for these 13 Twist1 positive tumors are provided in Table 3.1.  Among these 13 
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Twist1-positive tumors, 5 tumors showed significantly decreased Foxa1 protein 
compared with Twist1-negative tumors (Fig. 3.12F).  Twist1 protein levels were also 
negatively correlated with Foxa1 protein levels among these 13 Twist1-positive tumors 
(Fig. 3.12G).  These results demonstrate that the levels of Twist1 expression are 
negatively correlated with the levels of Foxa1 expression in human breast tumors. Thus 
we proposed that Twist1 could directly silence Foxa1 expression to promote de-
differentiation and metastasis of breast cancer cells.   
Figure 3.12. Twist1 expression is negatively associated with Foxa1 expression in 
human breast cancers.  A. Pearson’s Correlation test of Twist1 and Foxa1 mRNA 
expression levels in a published data set of human breast tumor cohort 118.    B and C. 
Expression levels of Twist1 (Panel B) and Foxa1 (Panel C) mRNAs in luminal and basal 
breast cancer cell lines. Data analysis was based on a published data set 119.  D. 
Pearson’s Correlation analysis between Twist1 and Foxa1 mRNA expression in breast 
cancer cell lines shown in Panels B and C.  E. Western blotting analysis of Twist1 and 
Foxa1 in human breast cancer cell lines. F and G. Representative images of IHC for 
Twist1 and Foxa1 in human breast tumors. Adjacent tumor sections were used 
for Twist1 and Foxa1 IHC (Panel F).  Twist1 and Foxa1 protein levels are inversely 
correlated in Twist1-positive breast tumors.  The r and p values were obtained by 
Pearson’s correlation analysis (Panel G).  The scale bar in Panel F, 50 µm. 
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Tumor Sample # ER PR HER2 Twist1 IRS Foxa1 IRS 
2011-07134C N N N 4 6 
2013-00701C P P N 4 6 
2013-00945C P P N 4 6 
2013-4269C P P N 4 6
2013-4275C P P N 4 6
2013-7639C P P N 4 4
2013-11189C P P P 4 6 
2013-11208C P P N 4 6 
2011-3968C P P N 5 5
2013-4773C P N N 5 6
2012-2420C N P N 6 4 
2012-3647C P P N 6 5
2013-7200C P P P 6 4
Table 3.1 Clinical information for Twist1-positive breast tumors. ER, estrogen 
receptor; PR, progesterone receptor; HER2, human epithelial growth factor receptor 2; 
IRS, immunoreactivity score; N, negative; P, positive 
3.9 Twist1 directly silences Foxa1 mRNA transcription by recruiting NuRD 
complex 
The luminal type breast cancer cell line MCF7 expresses ER and Foxa1, but not 
Twist1.  To establish a cellular model for investigating the molecular mechanisms 
responsible for Twist1 to regulate Foxa1 expression, we generated stable MCF7 cell 
lines with either the empty control vector (MCF7Ctrl) or the Twist1-expressing vector 
(MCF7Twist1).  Twist1 expression in MCF7Twist1 cells drastically decreased Foxa1 mRNA 
and protein levels (Fig. 3.13A).  Conversely, knockdown of Twist1 mRNA in the basal-
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like SUM1315 human breast cancer cells with high Twist1 and low Foxa1 expressions 
moderately increased the expression levels of Foxa1 mRNA and protein (Fig. 3.13B).  
However, ectopic expression of Foxa1 in either SUM1315 or BT549 breast cancer cells 
did not alter the expression levels of Twist1 mRNA and protein (Fig. 3.13 C and D).  
These results indicate that Twist1 suppresses Foxa1 expression, while Foxa1 does not 
regulate Twist1 expression. 
 
 
 
Figure 3.13. Twist1 silences Foxa1 expression in breast cancer cells.  A. Expression 
of Twist1 in MCF7 cells reduced Foxa1 mRNA and protein as measured by Q-PCR and 
Western blotting.  B. Knockdown of Twist1 mRNA in SUM1315 cells by using Twist1 
siRNA (siTwist1) increased Foxa1 mRNA and protein.  C and D. Overexpression of 
Foxa1 did not influence Twist1 mRNA and protein in either BT549 or SUM1315 cells. 
All experiments were repeated 3 times and the representative data are presented.  *, P< 
0.05 by Student’s t test. 
  
To examine whether Twist1 was recruited to the enhancer/promoter regions of the 
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Foxa1 gene, we performed chromatin immunoprecipitation (ChIP) assays by using a 
Twist1 antibody to pull down Twist1-associated genomic DNA in BT549 breast cancer 
cells and PCR to measure specific DNA regions of the Foxa1 enhancer or promoter.  We 
found that Twist1 was associated with the 5’ regulatory region at -1 kb from the 
transcriptional starting site (TSS), but it was not associated with -2, -3, -4 and -5 kb 
regions (Fig. 3.14A).  To examine the specific role of Twist1 in regulating the 
transcriptional activity of Foxa1 promoter, we constructed a Foxa1 promoter-luciferase 
(Foxa1-Luc) reporter containing 1.46-kb 5’ regulatory sequence with the Twist1-binding 
region (Fig. 3.14B).  Expression of Twist1 significantly decreased the activity of Foxa1-
Luc reporter in MCF7 cells.  As expected for positive and negative controls, Twist1 
decreased the activity of CDH1-Luc reporter, but did not affect the activity of CSF1-Luc 
reporter (Fig. 3.14C) 68, 106.  These results indicate that Twist1 is recruited to the 5’ 
regulatory region proximal to the Foxa1 promoter. 
In silico analysis of the proximal Foxa1 promoter region revealed 11 E-boxes.  Twist1 is 
more likely to bind two (EB3 and EB7) of these E-boxes as predicted by MatInspector 
Software (Genomatix) (Fig. 3.14B).  Deletion of either EB3 site in Foxa1-Luc (EB3M-
Luc) reporter or EB7 site in Foxa1-Luc (EB7M-Luc) reporter significantly relieved 
Twist1-repressed Foxa1 promoter activity in MCF7 cells.  Double deletions of both EB3 
and EB7 sites in Foxa1-Luc (EB3/7M-Luc) reporter additively relieved Twist1-repressed 
Foxa1 promoter activity (Fig. 3.14 B and D).  Since the activity of EB3/7M-Luc reporter 
was still partially silenced by Twist1 in MCF7 cells, Twist1 might also bind to other E-
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Figure 3.14. Twist1 directly bind to E-box element of Foxa1 promoter.  A .  
C h I P  assays performed with BT549 breast cancer cells and Twist1 antibody. Non-
immune IgG served as a negative control.  Immunoprecipitated DNA was assayed by 
real time PCR with primers specific to the Foxa1 5’ regulatory sequences at the 
indicatedlocations. B. The wild type and mutated constructs of the Foxa1 promoter-
luciferase reporter (Foxa1-Luc).  EB3M-Luc, EB7M-Luc and ER3/7M-Luc had mutated 
E-box3, E-box7 or both of them, respectively.  C & D. Cell transfection assays. Twist1 
expression in MCF7 cells repressed the activities of Foxa1-Luc (the tester) and CDH1-
Luc (a positive control), while it did not affect the activity of CSF1-Luc (a negative 
control) (Panel C).  Twist1 showed much less repression on the activities of EB3M-Luc, 
EB7M-Luc and EM3/7M-Luc versus Foxa1-Luc in MCF7 cells (Panel D).  Control 
cells were transfected with equal amount of the empty vector DNA. *, P< 0.05 by 
Student’s t test.   
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Figure 3.15. Mutation of Twist1-binding sites or knockdown of Twist1 mRNA 
increases Foxa1 promoter-luciferase (Luc) reporter activity in SUM1315 cells.  A. 
Knockdown of Twist1 mRNA in SUM1315 cells increased the activities of Foxa1-Luc 
(the tester) and CDH1-Luc (a positive control), but did not affect the activity of CSF1-
Luc (a negative control).  B. SUM1315 cells with normal Twist1 (shCtrl) or with Twist1 
knockdown (shTwist1) were transfected with wild type Foxa1 or mutant Foxa1 
promoter-Luc reporters as indicated.  Mutation of either E-box 3 (EB3M-Luc), E-box 7 
(EB7M-Luc) or both of them (EB3/7M-Luc) in the promoter sequence relieved Twist1-
mediated suppression and thus, increased the basal activities of the mutant promoters in 
control cells. For the same reason, knockdown of Twist1 expression showed less fold 
relieves of the three mutant Foxa1 promoter-Luc reporters when compared with the wild 
type Foxa1 promoter-Luc reporter. All experiments were repeated 3 times and the 
representative data with 3 technical replicates are presented as Mean ± SEM. *, P < 0.05 
by Student’s t test. 
boxes to repress the Foxa1 promoter.  On the other hand, in SUM1315 cells with 
endogenous Twist1 expression, mutation of EB3 and/or EB7 increased Foxa1-Luc 
reporter activity, while knockdown of Twist1 resulted in lesser fold increases in the 
mutant Foxa1 promoter activities versus the wild type promoter (Fig. 3.15 A and B). 
These results demonstrate that Twist1 can use both EB3 and EB7 sites to silence the 
transcriptional activity of the Foxa1 promoter.  We previously reported that Twist1 
recruits nucleosome remodeling deacetylase (NuRD) complex to repress CDH1 and estrogen 
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receptor (ERα) promoters 68, 120.  Here, our ChIP assays revealed that Twist1 was 
specifically recruited to the proximal promoter regions of both CDH1 and Foxa1 
genes in MCF7Twist1 cells (Fig. 3.16A). The endogenous HDAC2 and MTA2 
proteins, two of the NuRD complex components, were also recruited to the 
same chromatin regions of both CDH1 and Foxa1 genes in a Twist1 expression-
dependent manner (Fig. 3.16 B and C).  In agreement with the Twist1-recruited 
NuRD complex containing histone deacetylase activity, the levels of acetylated histone 
H3K9 (H3K9-ace) were markedly reduced in the same Twist1-binding regions of 
both CDH1 and Foxa1 genes in MCF7Twist1 cells versus MCF7Ctrl cells (Fig. 3.16D). 
Accordingly, RNA polymerase II recruited to these gene promoters was 
significantly reduced in MCF7Twist1 cells versus MCF7Ctrl cells (Fig. 3.16F). 
Furthermore, knockdown of Twist1 in SUM1315 cells decreased HDAC2 and MTA2 
recruitments and increased H3K9-ace and RNA polymerase II recruitment on Foxa1 
promoter (Fig. 3.17). These results demonstrate that Twist1 largely silences the 
transcriptional activity of the Foxa1 promoter by recruiting NuRD gene-repressing 
complex, the same mechanism as it represses CDH1 transcription. 
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Figure 3.16. Overexpressed Twist1 in MCF7 cells recruits NuRD complex to Foxa1 
promoter to repress its expression.  ChIP assays were performed in MCF7Ctrl and 
MCF7Twist1 stable cell lines using antibodies against Twist1 (Panel A), HDAC2 (Panel 
B), MTA2 (Panel C), H3K9-ace (Panel D) and RNA-PII (Panel E).  Non-immune IgG 
served as a negative control. Immunoprecipitated DNA was measured by real time PCR 
using primers for amplifying the Twist1-binding regions in the CDH1 gene (a positive 
control) and the Foxa1 gene (E-box3) as indicated. All experiments were repeated 3 
times and the representative data are presented as Mean ± SEM. 
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Figure 3.17. Knockdown of Twist1 mRNA reduced MTA2 and HDAC2 
recruitments but increased H3K9-Ace and RNA polymerase II (RNA-PII) 
recruitment to the Foxa1 promoter in SUM1315 cells. ChIP assays were performed 
with SUM1315 cells with normal Twist1 (shCtrl) or Twist1 knockdown (shTwist1) and 
with non-immune IgG (negative control) or antibodies against Twist1, HDAC2, MTA2, 
H3K9-ace or RNA-PII as indicated. The input and precipitated DNA samples were 
analyzed by real-time PCR that amplifies the E-box 3 region of the Foxa1 promoter. All 
experiments were repeated 3 times and the representative data with 3 technical replicates 
are presented as Mean ± SEM. *, P < 0.05 by Student’s t test. 
 
 
3.10 Twist1 silences Foxa1 expression through inhibiting AP-1-promoted 
activation of the Foxa1 promoter 
 
Computational analysis of the Foxa1 promoter region identified two AP-1 binding sites 
conserved in both human and mouse Foxa1 genes (Fig. 3.18A).  To define the role of 
AP-1 in regulating Foxa1 promoter, we expressed c-Jun and c-Fos and assayed their 
effects on the Foxa1-Luc reporter in MCF7 cells.  Expression of c-Jun and c-Fos 
significantly increased the activity of Foxa1-Luc reporter in a dose-dependent manner 
(Fig. 3.18B).  In contrast, knockdown of c-Fos in MCF7 cells drastically reduced the 
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expression levels of Foxa1 mRNA and protein (Fig. 3.18C).  Furthermore, deletion of 
either AP-1 site at bp -895 or bp -798 or both diminished AP-1-promoted activities of 
the Foxa1 AP1M1-Luc, AP1M2-Luc and AP1M1/2-Luc reporters (Fig. 3.18D).  These 
results demonstrate that AP-1 is a transcriptional activator of the Foxa1 promoter.  
 
We further performed ChIP assays to examine whether Twist1 could inhibit c-Fos from 
being recruited to the AP-1 sites of the Foxa1 proximal promoter region.  Indeed, Twist1 
expression in MCF7 cells abolished the recruitment of c-Fos to the Foxa1 proximal 
promoter region (Fig. 3.18E).  As a control, Twist1 did not inhibit c-Fos recruitment to 
the CSF1 promoter region 106. These results suggest that Twist1 plays a crucial role to 
repress AP-1-mediated activation of the Foxa1 promoter by preventing AP-1 recruitment 
to the Foxa1 proximal promoter region. As expected, expression of Twist1 in MCF7 
cells markedly repressed the transcriptional activity of the Foxa1-Luc reporter.  
However, Twist1 expression did not have an obvious effect on the activity of the Foxa1 
promoter with deleted AP-1 binding sites, including AP1M1-Luc, AP1M2-Luc and 
AP1M1/2-Luc reporters (Fig. 3.18F). Consistent results were also observed in SUM1315 
cells with Twist1 knockdown (Fig. 3.19 A and B). These results suggest that Twist1 
plays a role in silencing AP-1-mediated activation of the Foxa1 promoter. 
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Figure 3.18. Twist1 inhibits AP1-mediated activation of the Foxa1 promoter by 
inhibiting AP1 recruitment.  A. The two conserved AP1 sites in both human and 
mouse Foxa1 promoter regions.  B. Luciferase activity of MCF7 cells transfected with 
Foxa1-Luc plasmid with the empty vector (-) or c-Jun and c-Fos expression vectors. C. 
Q-PCR and Western blot assays showing Foxa1 mRNA and protein changes upon c-fos 
knockdown in MCF7 cells. D. Luciferase assay of MCF7 cells co-transfected with the 
indicated luciferase reporter and the empty vector (-) or c-Jun and c-Fos expression 
vectors.  E. ChIP assays performed with MCF7Ctrl and MCF7Twist1 cells and non-immune 
IgG (negative control) or c-Fos antibody as indicated.  The DNA fragment between the 
two arrowheads in Panel A was amplified by PCR from the immunoprecipitated DNA.  
Amplification of the known AP1-binding region by PCR in the CSF1 promoter served as 
a positive control. F. Luciferase assay of MCF7 cells co-transfected with the indicated 
luciferase reporter and the empty vector (Ctrl) or Twist1 expression plasmid. 
Experiments were repeated 3 times and the representative data are presented as Mean ± 
SEM.  * in Panels B–D, P<0.05 by Student’s t test. 
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Figure 3.19. Twist1 inhibits AP1-activated Foxa1 promoter activity in SUM1315 
cells.   A. Knockdown of Twist1 mRNA by shTwist1 increased c-Fos recruitment to the 
Foxa1 promoter. ChIP assays were performed with SUM1315 cells expressing non-
targeting shRNA (shCtrl) or shTwist1 that targets Twist1 mRNA and with control IgG or 
c-Fos antibody as indicated.  B. Mutation of AP-binding sites in the Foxa1 promoter 
decreased the promoter activity and knockdown of Twist1 expression markedly 
increased wild type Foxa1 promoter activity but only slightly increased the Foxa1 
promoter with mutated AP-1 sites. SUM1315 cells expressing shCtrl or shTwist1 were 
cultured in 24 well plates and transfected with the indicated Foxa1 promoter-Luc 
reporters. Luciferase assay was carried out 24 hours later after the transfection. 
Experiments were repeated 3 times and the representative data with 3 technical 
replicates are presented as Mean ± SEM.  * , P < 0.05 by Student’s t test. 
 
3.11 Twist1-silenced Foxa1 expression is not responsible for Twist1-induced cell 
morphological change but it mediates the expression of some Twist1-regulated 
genes 
 
To examine whether Twist1-silenced Foxa1 expression is responsible for Twist1-
induced morphology and gene expression changes in breast cancer cells, we stably 
restored Foxa1 expression in MCF7Twist1 cell lines (designated as MCF7Twist1+Foxa1 cell 
lines) with Twist1-silenced Foxa1 expression (Fig. 3.20A).  As expected, MCF7Ctrl cells 
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showed epithelial tumor cell morphology identical to their parent MCF7 cells, while 
MCF7Twist1 cells had an elongated spindle shape consistent with their EMT phenotype. 
MCF7Twist1+Foxa1 cells with restored Foxa1 expression showed a cellular morphology 
very similar to MCF7Twist1 cells (Fig. 3.20B), suggesting that the silenced Foxa1 
expression is not responsible for Twist1-induced morphological change of MCF7 cells.  
Furthermore, Twist1 expression effectively repressed E-cadherin, β-catenin, cytokeratin 
8 (K8) and ERα expression in MCF7Twist1 cells as compared to MCF7Ctrl cells, while 
restored Foxa1 expression only partially rescued K8 and ERα expression in 
MCF7Twist1+Foxa1 cells as compared to MCF7Twist1 cells (Fig. 3.20C). Moreover, Twist1 
strongly induced vimentin, integrin 1, integrin 5, and MMP9 expression but did not 
change fibronectin expression in MCF7Twist1 cells as compared to MCF7Ctrl cells. 
Restored Foxa1 expression had no effect on vimentin expression but inhibited Twist1-
induced integrin 1, integrin 5 and MMP9 expression and slightly increased 
fibronectin in MCF7Twist1+Foxa1 cells as compared to MCF7Twist1 cells (Fig. 3.20 C-F). In 
addition, Slug (Snail2) expression was increased in MCF7Twist1 cells versus MCF7Ctrl 
cells, but restored Foxa1 expression did not affect Twist1-induced Slug expression in 
MCF7Twist1+Foxa1 cells versus MCF7Twist1 cells. The expression levels of Snail1, Zeb1 and 
Zeb2 mRNAs were very low and remained unchanged in MCF7Ctrl, MCF7Twist1 and 
MCF7Twist1+Foxa1 cells.  These results suggest that silenced Foxa1 is not responsible for 
Twist1-induced mesenchymal cell morphology and most EMT marker gene expression, 
but responsible for permitting the expression of ER, K8 and other selective genes 
related to cell migration and invasion such as integrin 1, integrin 5 and MMP9. 
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Figure 3.20. The effects of silenced Foxa1 expression on Twist1-induced EMT cell 
morphogenesis and gene expression.  A. Western blot analysis of the indicated 
proteins in MCF7 parent cells, MCF7Ctrl cells, two lines (1 and 2) of MCF7Twist1 cells, 
and two lines (1 and 2) of MCF7Twist1+Foxa1 (T+F) cells.  B. The images of MCF7 parent, 
MCF7Ctrl, MCF7Twist1 and MCF7Twist1+Foxa1 (T+F) cells. Scale bar, 50 µm. C. Western 
blot analysis of the indicated proteins in the indicated cell lines. D-F. qPCR analysis of 
integrin 1, integrin 5 and MMP9 mRNA levels in the indicated cell lines. *, P < 0.05 
by Student’s t test. 
 
 
 
3.12 Silencing Foxa1 expression is required for Twist1 to promote migration, 
invasion and metastasis in breast cancer cells 
 
Expression of Foxa1 alone showed no effects on MCF7 cell migration and invasion. 
However, restored Foxa1 expression in MCF7Twist1+Foxa1 cells significantly suppressed 
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Twist1-induced cell migration on the culture plate and invasion through a Matrigel layer 
(Fig. 3.21 A and B). To examine whether Foxa1 could inhibit Twist1-promoted 
metastasis in vivo, we injected MCF7Ctrl, MCF7Foxa1, MCF7Twist1 and MCF7Twist1+Foxa1 
cells into the tail veins of SCID mice.  We examined the lung tissues 4 weeks after 
injection. We found metastatic tumor foci in 20% (1/5), 0% (0/5), 100% (5/5) and 20% 
(1/5) of lungs in mice received MCF7Ctrl, MCF7Foxa1, MCF7Twist1 and MCF7Twist1+Foxa1 
cells, respectively (Fig. 3.21C).  The average number of MCF7Twist1 cell metastasis foci 
developed in each lung was significantly increased versus the average numbers of 
MCF7Ctrl, MCF7Foxa1,and MCF7Twist1+Foxa1 cell metastasis foci per lung (Fig. 3.21D).  
Accordingly, the lung metastasis index reflecting the percentage of tumor area to lung 
tissue area was more than 25 fold higher in the recipient mice of MCF7Twist1 cells versus 
the recipient mice of MCF7Ctrl or MCF7Twist1+Foxa1 cells (Fig. 3.18E).  To examine if 
restored Foxa1 could partially reverse the Twist1-induced basal tumor phenotype in 
vivo, we injected MCF7Ctrl, MCF7Foxa1, MCF7Twist1 and MCF7Twist1+Foxa1 cells into the 
mammary gland fat pads of SCID mice to form xenograft tumors and profiled the 
expression levels of well-established luminal and basal breast cancer marker genes. 
Luminal markers including FOXA1, PGR, GRP160, BAG1, BLVRA, PDEF, XBP1 and 
MUC1 were repressed and basal markers including JAG1, EGFR, FOXC1, CK5, 
CDC20 and ITGB1 were induced in MCF7Twist1 tumors versus MCF7Ctrl and most 
MCF7Foxa1 tumors. Restored Foxa1 expression increased the expression of many luminal 
markers including BLVRA, PDEF and XBP1 and decreased the expression of many 
basal markers including JAG1, CK5, CDC20 and ITGB1 in MCF7Twist1+Foxa1 tumors 
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versus MCF7Twist1 tumors (Fig. 3.22A). Again, Twist1 promoted MCF7Twist1 tumor 
metastasis, while restored Foxa1 inhibited MCF7Twist1+Foxa1 tumor metastasis in SCID 
mice (Fig. 3.22 B and C).  Together, these results demonstrate that Twist1-repressed 
Foxa1 expression may be important for BLBC progression and is required for Twist1-
promoted migration, invasion and metastasis of breast cancer cells. These results 
demonstrate that Twist1-mediated downregulation of Foxa1 expression is required for 
TWISTS1-promoted breast cancer cell metastasis.  
Figure 3.21. Restored Foxa1 expression inhibited Twist1-promoted migration, 
invasion and metastasis of breast cancer cells. A & B.  Cell migration and invasion 
assays for MCF7 parent, MCF7Ctrl, MCF7Foxa1, MCF7Twist1 and MCF7Twist1+Foxa1 cells. *, 
P<0.05 by Student’s t test.  C. Lung photographs of SCID mice after receiving 
intraveinous injection of MCF7Ctrl, MCF7Foxa1, MCF7Twist1 or MCF7Twist1+Foxa1 cells for 4 
weeks.  Asterisks indicate visible metastasis nodules.   D.  Metastasis nodules identified 
on the H&E-stained serial lung sections of SCID mice (n=5) injected with MCF7Ctrl, 
MCF7Foxa1, MCF7Twist1 or MCF7Twist1+Foxa1 cells for 4 weeks.  **, P<0.01 by Student’s t 
test.  E. Metastasis indexes were presented as the average ratios of tumor areas to 
lung areas measured on the images taken from H&E-stained serial lung sections.  **, 
P<0.01 by Student’s t test.  
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Figure 3.22. Restored Foxa1 expression increased the expression of most Twist1-
suppressed luminal marker genes and decreased the expression of most Twist1-
promoted basal marker genes in the xenograft tumors in mice.  A. MCF7Ctrl, 
MCF7Foxa1, MCF7Twist1 or MCF7Twist1+Foxa1 cells were injected into the second pair 
mammary gland fat pads of each 8-week-old female SCID mouse (4 × 106/fat pad). Five 
mice were used for each group. Injected mice were fed drinking water containing 1µg/ml 
of 17β-estradiol. In 6 weeks after cell injection, 5, 4, 9 and 7 tumors were observed in 
mice receiving MCF7Ctrl, MCF7Foxa1, MCF7Twist1 or MCF7Twist1+Foxa1 cells, respectively. 
Mice were euthanized and the xenograft tumors were collected. Total RNA samples 
were prepared from 4 tumors in each group and qPCR analyses were performed to 
measure the mRNA levels of the indicated luminal and basal marker genes. Their 
relative expression levels were obtained by normalized to the level of b-actin mRNA 
in each sample.  Four tumor RNA samples in each group were analyzed in duplicates 
and data are presented as Mean ± SEM. One-Way ANOVA was performed to analyze 
the statistical differences among groups. * and **, P < 0.05 and 0.001; NS, not 
significant.  B & C. The lungs were isolated from the above mice injected with 
MCF7Ctrl, MCF7Foxa1, MCF7Twist1 or MCF7Twist1+Foxa1 cells and examined for 
metastasis by counting the number of metastasis nodules and measuring the ratio of 
metastatic tumor area to total lung area (Metastasis Index) on the H&E-stained lung 
sections.   
76
3.13 Breast tumor patients with high Twist1 and low Foxa1 expression exhibit 
poor distant metastasis-free survival 
To assess the clinical relevance of the Twist1-Foxa1 regulatory axis in human breast 
cancer progression, we analyzed the association between the expression levels of Twist1 
and Foxa1 and the clinical outcomes in a large breast cancer cohort with distant 
metastasis-free survival (DMFS) data 121.  The whole cohort of patients was divided into 
four groups according to the median Twist1 and Foxa1 expression.  The 
Twist1High/Foxa1Low subgroup exhibited significantly worse DMFS than the 
Twist1Low/Foxa1High and the Twist1High/Foxa1High subgroups.  DMFS of the 
Twist1Low/Foxa1Low subgroup is not significantly different from the DMFS curves of the 
other three groups (Fig. 3.23A). Further analyses revealed that the percentages of 
Twist1LowFoxa1high and Twist1HighFoxa1High subgroup tumors in luminal A and luminal 
B subtypes are much higher than those in Basal-like and HER2-positive subtypes, while 
the percentages of Twist1Low/Foxa1Low and Twist1high/Foxa1Low tumors in luminal A and 
luminal B subtypes are much lower than those in the more aggressive basal-like and 
HER2-positive subtypes (Fig. 3.23B).  Interestingly, when the cohort was further 
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subgrouped into luminal A, luminal B, HER2-positive and basal-like subtypes, only the 
Twist1high/Foxa1Low patients with luminal A tumors exhibited significantly worse DMFS 
as compared to Twist1Low/Foxa1High and Twist1High/Foxa1High patients with luminal A 
tumors (Fig. 3.23 C-F).  These results suggest that Twist1-mediated repression of Foxa1 
expression plays an important role in breast cancer metastasis and Foxa1 can effectively 
inhibit metastasis in tumors with high expression of both Twist1 and Foxa1. 
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Figure 3.23. The association of Twist1 and Foxa1 expression levels with the clinical 
outcomes of the breast cancer patients.  A. The distant metastasis-free survival 
(DMFS) curves of women with breast tumors expressing high or low levels of Twist1 
and Foxa1 as indicated.  The cohort (n=1609) was divided into high and low expression 
subgroups by the median.  B. The distribution of patients with the indicated expression 
patterns of Twist1 and Foxa1 mRNAs in the 4 subtypes of breast cancer.  The number of 
cases in each group is indicated above each bar. C-F.10-year DMFS curves for 
luminal A (Panel C), luminal B (Panel D), HER2-positive (Panel E), and basal-like 
(Panel F) breast cancer patients with different expression levels of Twist1 and Foxa1 
mRNAs.  Sample number (n) is indicated for each subgroup. **, P<0.01 by Log-rank 
test.  
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4. SUMMARY AND DISCUSSION
In this study, we developed the novel TVA/RCIP mouse model system in which deletion 
of a floxed gene such as Twist1 and expression of an oncogene such as PyMT happen 
simultaneously in the RCIP virus-infected LECs expressing TVA.  This model has 
several unique advantages. Firstly, TVA is only expressed in the mammary LECs in 
MMTV-TVA mouse line 105 and RCIP virus only infects the TVA-expressing cells, 
allowing specific delivery of Cre recombinase and PyMT (or any oncogene) to these 
mammary LECs.  Secondly, the intraductally introduced RCIP virus only infects a small 
population of the mammary LECs expressing TVA and transform these cells into tumor 
cells.  This closely simulates spontaneous tumorigenesis in humans with tumor initiation 
and growth in a normal surrounding cellular environment.  Thirdly, the Cre-coding 
sequence is located before the short IRES and the PyMT sequences, which makes Cre 
expression much higher than PyMT expression and guarantees efficient knockout of the 
floxed genes in the tumor cells.  Finally, the single virus construct-mediated co-
expressions of Cre and PyMT also save time and resources for crossbreeding of multiple 
mouse lines. These unique features make this TVA/RCIP model system very useful for 
characterizing the role for any floxed genes during the process of mammary tumor 
initiation, progression and metastasis. 
Using TVA/RCIP system, we selectively induced mammary tumorigenesis from Twist1 
null LECs in mice.  We found that Twist1 is not expressed in normal LECs and the RCIP 
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virus-induced initiation and growth of mammary tumors derived from LECs with or 
without Twist1 knockout are the same, indicating that Twist1 is not required for 
mammary tumor formation in LECs.  Tumor cell proliferation, apoptosis and 
macrophage recruitment all showed no significant difference. These results of 
endogenous Twist1 function further validates the previous studies showing knockdown 
of Twist1 in breast cancer cell lines did not affect their proliferation in culture and 
xenograft tumor growth in mice 26, 68.  Interestingly, a recent study reported an essential 
role of Twist1 in developing skin tumors, suggesting the role of Twist1 in carcinogenesis 
may depend on cell types 122.  Another study123 using pancreatic tumor model showed 
that knock out of Twist1 or Snal1 is dispensable for initiation and progression of primary 
pancreatic cancer. Our data is consistent with the pancreatic study that Twist1 knockout 
does not influence breast tumor initiation, proliferation, apoptosis or macrophage 
recruitment. 
Our results showed Twist1 is expressed in a small population of tumor cells at advanced 
stages at levels similar to the stromal cells, indicating that only certain primary tumor 
cells gain Twist1 expression during tumor progression.  We did not find lung metastasis 
in mice with palpable mammary primary tumors that have been developed for 6 weeks, 
but did find extensive lung metastases in mice with palpable mammary primary tumors 
that have been developed for 10 weeks.  These results suggest that Twist1 expression is 
associated with metastasis in mammary tumors with functional Twist1 gene.  More 
importantly, Twist1 null tumor cells yielded significantly fewer lung metastasis than 
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tumor cells with functional Twist1, indicating that the functional Twist1 gene promotes 
tumor cell metastasis. Together, we conclude that Twist1 plays a tumor cell-autonomous 
function to promote metastasis and validate the results of previous studies showing that 
knockdown of Twist1 in established breast cancer cell lines inhibits their metastasis in 
immune-defective host mice 26, 64, 68.  
We then examined EMT markers by IF staining and found that Twist1 expressing tumor 
cells indeed showed EMT marker transition: decreased E-cadherin but increased 
vimentin, suggesting the association of EMT with lung metastasis.  However, because 
we found metastatic tumor cells in the lung still maintain epithelial phenotype and do not 
express Twist1, it remains debatable whether the initial Twist1-expressing tumor cells in 
the mammary glands physically metastasize to the lung.  A recent study using a 
squamous cell carcinoma mouse model with inducible Twist1 expression nicely 
demonstrated that although Twist1 expression strongly promotes tumor cell invasion and 
intravasation, turning off Twist1 expression is required for the disseminated tumor cells 
to establish metastasis in a distant organ 49.  According to this model, it is possible that 
Twist1 expression in primary tumor cells induces partial EMT and drives local invasion 
and intravasation. Then, Twist expression is turned off in the tumor cells of lung 
metastases.  However, it is also possible that the initial Twist1-expressing tumor cells 
did not metastasize to the lung, but these cells induce their surrounding Twist1-negative 
tumor cells to metastasize. Two recently published studies support this model 123, 124. 
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Since Twist1 is a transcription factor, it should promote breast cancer metastasis through 
either inhibiting or enhancing its target gene expression.  In this study, we found that 
Twist1 expression negatively correlates with Foxa1 expression in both mouse and 
human breast tumors.  Foxa1 expression is associated with LBC which has a good 
prognosis. Meanwhile Twist1 is associated with BLBC which has a poor prognosis due 
to its potential to drive cell invasiveness and metastasis. However, the regulatory and 
functional relationship between Twist1 and Foxa1 in breast cancer progression remains 
unknown. In this study, we found Twist1 expression negatively correlates with Foxa1 
expression in human breast cancer cells and tumors. Mechanistically, Twist1 directly 
associates with Foxa1 promoter to recruit NuRD complex and prevent AP-1 binding to 
Foxa1 promoter, resulting in decreased H3K9 acetylation, reduced RNA polymerase II 
recruitment and silenced Foxa1 expression. It is conceivable that constitutive AP-1 
binding in LBC cells with no Twist1 plays a major role to maintain a high level of Foxa1 
expression and thus a luminal phenotype. Twist1 expression in partial or full EMT breast 
cancer cells may partially or fully inhibit AP-1 recruitment to Foxa1 promoter through 
NuRD complex-mediated changes in histone codes and thus reduce or silence Foxa1 
expression, causing breast cancer progression toward BLBC. Therefore, our findings 
indicate that Foxa1 is a direct target of Twist1 during breast cancer progression and 
provides a possible new mechanism for the loss of Foxa1 during breast cancer 
progression from a luminal ER-positive subtype to an ER-negative BLBC subtype. 
In agreement with the established function of Twist1 64, ectopic expression of Twist1 in 
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MCF7 cells induced a mesenchymal morphology and gene expression signature but 
decreased epithelial signature. Using this cellular model, we addressed how much the 
Twist1-silenced Foxa1 expression contributes to Twist1-induced mesenchymal 
morphogenesis and gene expression in breast cancer cells by restoring Foxa1 in Twist1-
expressing MCF7 cells.  Interestingly, though previous studies have shown Foxa1 
represses EMT-linked mesenchymal morphogenesis in pancreatic cancer cells 125, we 
found that restored Foxa1 did not change the mesenchymal cell morphology induced by 
Twist1 in MCF7Twist1+Foxa1 cells.  In agreement with this, restored Foxa1 did not rescue 
the expression level changes of either canonical epithelial genes such as E-cadherin and 
-catenin or mesenchymal genes such as vimentin and Slug, which are inhibited or 
induced by Twist1 expression in MCF7 cells, respectively. We then also estimated the 
role of Foxa1 silencing in EMT by comparing the genes regulated by Foxa1 in the LBC 
cells to the previously published EMT signature genes 101, 126. Among the 1118 Foxa1-
regulated genes 101, we only found ARHGAP8, LMCD1, NMU, PPAP2B, PRKCH and 
SLPI in the 251 EMT signature gene lists 126. None of these 6 genes has been shown to 
regulate the mesenchymal morphogenesis of breast cancer cells. Together, these findings 
suggest that Twist1-silenced Foxa1 expression is not a major regulatory pathway for the 
mesenchymal morphogenesis and for the expression of most typical EMT signature 
genes in breast cancer cells. 
Interestingly, restored Foxa1 does partially rescue ER and K8 expression and strongly 
downregulate Twist1-induced integrin 1, integrin 5 and MMP9 expression. Since 
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ER and K8 are markers of the LBC and integrins 1 and 5 are preferentially 
expressed in BLBC, it is conceivable that Twist1-silenced Foxa1 expression plays a 
crucial role in promoting BLBC progression. Foxa1 could either directly or indirectly 
regulate these genes. It has been reported that Foxa1 upregulates but Twist1 directly 
represses ER expression 12, 91, 120. The results of the present study suggest that both the 
loss of Foxa1-mediated activation due to Twist1-silenced Foxa1 expression and the 
Twist1-mediated active repression are required for shutting down ER expression and 
developing endocrine resistance during breast cancer progression toward BLBC. These 
interpretations are consistent with the previous studies showing that Foxa1 expression is 
associated with good responses to endocrine therapy and the loss of Foxa1 is associated 
with BLBC progression 93, 94, 97-102. More importantly, restored Foxa1 robustly inhibited 
Twist1-promoted migration, invasion and metastasis. These could be partially attributed 
to the downregulation of Twist1-induced expression of MMP9 and integrins 1 and 5, 
since these proteins are known to promote cell invasiveness and metastasis 110, 127-131. In 
addition, we demonstrate that Twist1 expressed in MCF7 cells increased most BLBC 
markers but decreased most LBC markers in these cell-derived xenograft tumors, while 
restored Foxa1 in Twist1-expressing MCF7 cells decreased many BLBC markers but 
increased many LBC markers. These results further support the notion that Twist1-
repressed Foxa1 expression may play an important role to promote BLBC progression. 
In previous studies, the role of Twist1 in promoting metastasis was largely attributed to 
its capability to induce EMT and enhance cancer stem cell (CSC) features 26, 51, 64, 71. 
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Now, the consensus from present and previous studies suggests that Twist1 may serve as 
a master regulator in breast cancer progression by regulating multiple genes involved in 
multiple pathways. On one hand, Twist1 may regulate one subgroup of genes, such as 
downregulating E-cadherin and ER 12, 68, 120 and upregulating Bmi1, AKT2, Wnt5a and 
vimentin 70, 85, 132 to promote EMT, CSC features, cell migration, invasion and 
metastasis. On the other hand, Twist1 may regulate another subgroup of genes, such as 
upregulating PDGFR to induce invadopodia formation for cell invasion 72 and 
downregulating Foxa1 to decrease ER, CK8 and other LBC markers and increase 
integrin α5, integrin β1, MMP9 and other BLBC markers for promoting BLBC 
progression and breast cancer cell migration, invasion and metastasis. Although these 
multiple Twist1-regulated genes and pathways may not be equally important, they may 
work cooperatively to drive breast cancer progression and metastasis. A single targeting 
event such as silencing Foxa1 or upregulating AKT2 can be required but may not be 
sufficient for Twist1-promoted migration, invasion and metastasis of breast cancer cells. 
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Figure 4.24. Summary of Twist1-Foxa1 regulatory axis in breast cancer cells 
Analysis of a large cohort dataset showed that tumors with Twist1HighFoxa1Low 
expression are associated with worse DMFS versus Twist1LowFoxa1High and 
Twist1HighFoxa1High tumors, which supports the notion that Twist1-silenced Foxa1 
expression can promote breast cancer metastasis.  Interestingly, this association is only 
observed in the mixed subtypes and luminal A subgroup, but not in the luminal B, 
HER2-positive or basal-like subgroups. We noticed that the tumor numbers with each 
expression profile are more evenly distributed in the luminal A and luminal B subgroups 
versus basal-like and HER2-positive subgroups.  The latter two subtypes contain too few 
tumors with Twist1LowFoxa1High and Twist1HighFoxa1High expressions and thus do not 
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support a valid statistical analysis to compare Twist1LowFoxa1High or Twist1HighFoxa1High 
tumors with Twist1LowFoxa1Low or Twist1HighFoxa1Low tumors.  Nevertheless, the facts 
that Twist1 is expressed at high levels in more than 40% of basal-like and HER2-positive 
tumors and Foxa1 is expressed at low levels in 96% of basal-like and 77% of HER2-
positive tumors also support the notion that silenced Foxa1 expression is associated with 
more malignant breast cancer subtypes.  For the luminal B subtype group, other factors 
in addition to Twist1 and Foxa1 may determine DMFS of these patients. 
Analysis of tumor tissue microarrays by IHC also revealed an overall negative 
correlation between Twist1 and Foxa1 proteins. However, we did not found many 
Twist1-positive tumors from the examined breast tumor microarrays either because of 
too few BLBCs in the cohort or missed identification of some positive tumors due to the 
small area of tissue microarrays which are insufficient to cover heterogeneous regions 
for Twist1 expression in a tumor. IHC revealed that Twist1 is usually expressed only in 
a small subpopulation of tumor cells or a small region in a tumor. Most of these Twist1-
positive tumors also contain many Foxa1-positive luminal tumor cells. These double 
positive tumors may contain Twist1-positive/Foxa1-positive, Twist1-positive/Foxa1-
negative and/or Twist1-negative/Foxa1-positive cells. These observations support the 
notion that Twist1 is expressed in a subset of breast tumor cells and that Twist1 
represses Foxa1 expression and drive EMT to promote BLBC progression from this 
subset of tumor cells. 
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In summary, we found that endogenous Twist1 mainly promotes breast cancer 
invasiveness and metastasis with no obvious function in affecting primary tumor 
development. Twist1 is expressed is in a small population of tumor cells and its 
expression associates with EMT phenotype, invasiveness and metastasis. We further 
found that Twist1 directly represses the transcriptional activity of the Foxa1 promoter in 
breast cancer cells. Twist1-silenced Foxa1 expression is largely responsible for Twist1-
mediated migration, invasion and metastasis but less responsible for Twist1-induced 
EMT morphology. On the other hand, silencing Foxa1 by Twist1 in breast cancer 
strongly promotes the transition from the luminal to basal gene signatures. These results 
not only uncover the mechanism of Foxa1 silencing in BLBC but also provide a new 
mechanism of Twist1’s role in BLBC progression. Therefore, targeting Twist1 in BLBC 
treatment may be an effective approach to inhibit invasion and metastasis. 
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